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ABSTRACT

THE SEARCH FOR NOVEL ANTIBIOTIC COMPOUNDS THROUGH
MOLECULAR MODELING AND STRUCTURE FUNCTION ANALYSIS OF CspE
IN E. coli K12

By
Andre Duane Samuel
August 2014
Dissertation supervised by Nancy Trun, PhD
Escherichia coli K12 has the capacity to express nine Csp (Cold shock-related
protein) gene products (CspA-I). These proteins share between 29 and 83 percent identity
in their amino acid sequences and only one, CspA, has a solved crystal structure. One of
the Csps shown to be involved in chromosome condensation is a 6.3 kDa protein called
CspE and deletion studies of its homologues in Bacillus subtilis show that at least one of
the Csp proteins is required for cell viability. All of the Csp proteins studied to date bind
to single stranded nucleic acids. Knowing that at least one of these proteins is required for
cell viability and that the homologues of this protein share high similarities in both
structure and function, I have used in silico and in vitro methods to accurately predict
structure-function correlations that can be targeted for inhibition by small molecules.
Using the structural information of the homologue, CspB, in B. subtilis, co-crystalized
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with and without its ligand, I have modeled the remaining eight unsolved structures of the
Csps in E. coli K12. Using molecular modeling and structures from commercially
available databases, I found two lead compounds that could potentially inhibit CspE
function. My data suggest that successful small molecule inhibition of CspE could also
effect enough of the remaining 8 Csp homologues in E. coli K12 to impact cell viability
and provide a means to finding lead compounds for novel antibiotic development.
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INTRODUCTION
The Battle Against Multidrug Resistant Bacteria
Modern medicine was greatly advanced by the accidental discovery of the world’s
first antibiotic by Alexander Flemming in 1928 (1). The discovery of penicillin,
produced by Penicillium notatum, paved the way for the discovery of many more
antibiotic compounds. These compounds range in mechanism of action from being
inhibitors of cell wall synthesis, protein synthesis, nucleic acid synthesis, or membrane
function, to being antimetabolites (2) (Table 1).
Certain antibiotics are used preferentially for specific diseases. For example
rifampin, which interferes with the process of nucleic acid synthesis, is commonly used
in the treatment of tuberculosis (3). Other antibiotics are only effective under certain
conditions. The sulphonamides and folic acid analogs work by interfering with metabolic
pathways (3). Folic acid is made of PABA (para-aminobenzoic acid) and glutamate. The
sulphonamides are analogs that compete with PABA for incorporation into the folic acid
molecule. This inhibition of folic acid synthesis prevents the synthesis of purines in the
bacterial cell. However, these drugs are only effective in the absence of significant levels
of thymine. The presence of large amounts of thymine makes these drugs ineffective
against bacteria (3).
In prior years, these powerful allies in the battle against bacterial diseases led to
the general belief that any bacterial infection could be controlled by antibiotic therapy.
Today, to the contrary, we find ourselves with numerous
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Table 1. The common antibiotics and their targets in cellular processes.
Target

Antibiotic

Cell Wall Synthesis
Inhibitors

beta-lactams
fosfomycins
glycopeptides

Protein Synthesis Inhibitors

Aminoglycosides
Gentamicin
Tobramycin
Amikacin
Glycylcyclines
Tigecycline
MLSK(macrolides, lincosamides, streptogramins, ketolides)
Erythromycin
Clindamycin
Quinupristin-Dalfopristin (Synercid)
Clarithromycin
Azithromycin
Telithromycin
Oxazolidinones
Linezolid
Phenicols
Chloramphenicol
Tetracyclines
Tetracycline
Doxycycline

Nucleic Acid Synthesis Inhibitors

Rifampin
Furanes
Quinolones
Metronidazole

Membrane Function Inhibitors

Lipopeptides
Polymyxins
Polymyxin B
Colistin
Cyclic Lipopeptides
Daptomycin

Antimetabolites

Folic Acid synthesis
Sulfonamides
Trimethoprim
Mycolic Acid synthesis
Isoniazid
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strains of antibiotic resistant bacteria. For example, vancomycin was introduced for the
treatment of methicillin resistance in both Staphylococcus aureus and coagulase-negative
Staphylococci in 1958 (4). Vancomycin resistance was originally very difficult to induce
and it was strongly believed to be very unlikely to transpire in a clinical setting (5). This
was essentially true until 1979, when reports of vancomycin resistant Staphylococci
appeared (4). Vancomycin resistance initiated serious public health concerns. This was
based mainly on the fact vancomycin was, for so long, the preferred choice to treat
bacterial diseases caused by Gram-positive multidrug resistant organisms. The trend to
antibiotic resistance in bacteria is accelerating (6-11).
The emergence of multidrug-resistant pathogenic bacteria has further
compounded an already critical issue. Multidrug-resistant tuberculosis (MDR) is an
excellent example. The MDR strains of Mycobacterium tuberculosis have reached
epidemic proportions in many parts of the world, being identified in as many as 50
countries (3). These once treatable bacterial infections are now emerging as untreatable
and increasingly fatal diseases (3).
The bacterium, Escherichia coli, typically exists as a commensal microorganism
in both humans and animals. There are a number of pathogenic variants of E. coli that can
lead to intestinal and extra-intestinal infections, such as gastroenteritis, urinary tract
infections, meningitis, peritonitis, and septicemia (12, 13). Treatment options for
bacterial diseases vary, depending on the nature of infection. For example, for urinary
tract infections, trimethoprim/sulfamethoxazole and fluoroquinolones are treatments of
choice (14). For Shiga toxin–producing E. coli infections, antimicrobial drug therapy is
not recommended because pre-diarrheal administration of antibiotics that prevented
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detectable intestinal colonization were not effective and the mechanisms of the disease
aren’t fully understood (15).
E. coli can be used as a sentinel for monitoring antimicrobial drug resistance in
fecal bacteria because it is found more frequently in a wide range of hosts, acquires
resistance easily (10), and is a reliable indicator of resistance in the Salmonellae (16). A
recent study has documented antimicrobial drug resistance in bacteria from humans and
animals and associated emergence of resistance with approval of new antimicrobial
classes. Of the samples tested, E. coli isolates from animals showed an increasing trend in
resistance to 11 antimicrobial agents: 1) ampicillin, 2) sulfonamide, 3) tetracycline, 4)
cephalothin, 5) trimethoprim/sulfamethoxazole, 6) streptomycin, 7) chloramphenicol, 8)
cefoxitin, 9) gentamicin, 10) amoxicillin/clavulanic acid, and 11) kanamycin (17). The
human E. coli isolates showed an increasing trend in resistance to ampicillin,
sulfonamide, and tetracycline (17). These data suggest that E. coli can serve as a model
for studying antimicrobial development and resistance to new compounds.
Research shows that every year over 13 million deaths worldwide are attributed to
the emergence of new infectious diseases or to the re-emergence of diseases previously
thought well-controlled (18). During the 1980s, the consensus among pharmaceutical
companies was that there were enough antibiotics already on the shelf and research
efforts were redirected elsewhere, focusing on lucrative treatments for other diseases such
as statins for the control of cholesterol levels (19). Many pharmaceutical companies
closed their antimicrobial research departments and development of new antimicrobial
agents has remained stagnant (6). Given that the pharmaceutical companies largely
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abandoned their efforts on antimicrobial research and development, we are now faced
with trying novel approaches to search for new antimicrobial targets.
The emergence of multiple drug resistant bacteria has presented the scientific
community with the need and urgency to find novel antibiotic compounds. A number of
researchers have placed their focus on Multidrug Efflux Systems (MES) and inhibitors of
MES (18, 20). Multidrug efflux systems are membrane transporter proteins that render
the cell antibiotic resistant by transporting the antibiotic out of the cell (21, 22). MES are
one of the major components of resistance to many classes of antimicrobial compounds
that pump the antibiotic out of the cell (9). They carry out essential roles in cellular
metabolism and differ from each other in membrane topology, energy coupling
mechanisms, and most importantly, substrate specificities (23). The identification of
natural substrates and inhibitors of efflux systems is an active and expanding research
topic (18, 20) and the MES pumps are important new target molecules for novel
antibiotics.
Based on their sequence similarity, MES have been classified into the following
six superfamilies: ATP-binding cassettes (ABC), multidrug and toxic compound efflux
(MATE), resistance-nodulation cell division (RND), small multidrug resistance family
(SMR), multi- antimicrobial extrusion protein family, and multidrug endosomal
transporters (MET) (24). These are all found in microorganisms with the exception of the
MET family, which appears to be restricted to higher eukaryotes (24). Representatives of
all groups are, however, expressed in mammalian cells (24). The ABC transporters are
classified as the largest superfamily, containing seven subfamilies (designated A to G)
based on sequence and structural homology (25). The molecular mechanism of the
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transporter substrate recognition, the kinetics, the stoichiometry and the features of the
antiport process are still under investigation (18).
While these targets have been successfully used to find inhibitors, there are still
some fundamental challenges associated with antimicrobial drug development for efflux
systems. Primarily, the large number of classes of these proteins and protein complexes
and their existence in both prokaryotes and eukaryotes makes it more difficult to find
inhibitors of only the microbial targets. The diversity in substrate specificity of the MES
complexes also implies difficulty in finding one small molecule to inhibit more than one
protein target.
Finding new target molecules for novel antibiotic development requires selective
toxicity. In other words it should posses pharmacologic properties that kills or inhibits
disease-causing microorganisms without harm to the host. This requires knowledge of a
target in the microbial organism that is unique to that organism. Once a potential drug
has been found it must then be examined for its affect on the target organism as well as
the mammalian host of that organism. The antibiotic must be able reach the target tissue
of the host without being fully metabolized and in concentrations lethal to the
microorganism. The process has historically required at least a decade of research and
clinical testing, as well as a several million dollar investment, before a potential antibiotic
can go to market.
It is clear from past and present research that more cellular components and
processes need to be considered as potential antibiotic targets. To be an effective target,
the cellular component should be essential so that preventing it from functioning results
in cell death. The potential target should be present in a variety of bacteria so that any
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new antimicrobial compound has the widest possible usage. The best-case scenario is if
the new target is not present in eukaryotic cells. If it is present, the target needs to be
different enough from its bacterial counterpart so that an antibiotic does not interfere with
eukaryotic cell function.

The Chromosome Condensing Proteins in E.coli and their Potential as Novel
Antibiotic Targets
Studies have shown that one of the most heavily investigated targets for
antimicrobial development includes DNA replication and the DNA-protein interactions
that make replication possible (26). The number of investigators pursuing these targets as
antimicrobial compounds has almost doubled from 2011 to 2013 (26). The quinolones
target DNA-protein interactions and were very successful until resistance to these
compounds began to emerge (26, 27).
The quinolones target two topoisomerases that are involved in DNA replication,
DNA gyrase and topoisomerase IV (28). These antimicrobial compounds work by
forming a ternary complex with the target enzyme and DNA, thus disrupting DNA
replication and triggering cell death (28). The emergence of quinolone resistant bacteria
has lead to development of new quinolone derivatives and other topoisomerase inhibitors
(28). Given that targeting DNA-protein interactions is a widespread strategy for
developing antibiotics, I have chosen to examine whether there is potential for novel
antibiotic development with DNA binding proteins that are involved in chromosome
folding as the target.
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An intact and properly folded bacterial chromosome is crucial to maintaining
gene regulation, DNA replication, and ultimately, cell viability. In E. coli K12, a single
4,639 million base pair circular chromosome is compacted into approximately 100
independently supercoiled domains that form a rosette structure, referred to as the
nucleoid (29). This structure is maintained by a number of cellular components including
both bacterial nucleoid-associated proteins that play a key role in the organization,
replication, segregation, repair and expression of the bacterial chromosome and various
types of RNA (30).
While many cellular components contribute to this tightly compacted structure,
DNA-binding proteins have been shown to play a vital role in condensing the
chromosome into its tightly compacted structure (31-36). In eukaryotic cells, histones
bind and compact DNA, providing means for not only compaction of the chromosome
but gene regulation as well (37). In E. coli, the main condensing protein is MukB, a
SMC-like protein similar to eukaryotic structural maintenance of chromosome
polypeptides (38). Other proteins that have been shown to play a role in bacterial
chromosome condensation include H-NS (histone-like nucleoid structuring protein), HU
(heat unstable protein), Fis (Factor for inversion stimulation) and the Csp (Cold Shockrelated Protein) family of proteins (39).

MukB
The 177 kDa MukB Protein of E. coli is a structural and functional analogue of
the SMC family of proteins found in bacteria (40-43). This protein forms a coiled-coiled
dimer and has been shown to bind and condense DNA without the requirement for ATP
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(42, 44-46). MukB contains an N-terminal globular domain, which contains a nucleotide
binding consensus sequence and a C-terminal domain that participates in DNA binding
activity (42, 44-46). A deletion of the mukB gene results in cells that display
hypersensitivity to novobiocin, which inhibits DNA gyrase. This suggests that the
function of the MukB protein relates to superhelicity or maintaining the threedimensional structure of chromosomal DNA (40, 47, 48). The MukB deletion also shows
an increase in cells without DNA (anucleate cells) and a hypersensitivity to fast growth
rates. Recently it has been demonstrated that MukB interaction with TopoIV stimulates
catalysis by TopoIV (49). While MukB plays an important role in bacterial chromosome
condensation, deletion of the mukB gene is a conditionally lethal event. MukB is not an
essential protein (38), decreasing its potential as a novel antibiotic target.

H-NS (Histone-like Nucleoid Structuring Protein)
The H-NS protein is 15.4 kDa and binds single-stranded DNA (ssDNA) with no
sequence specificity but with a preference for DNA in a curved conformation (50)
(Figure 1). There are three distinct domains: an N-terminal domain that has been shown
to be responsible for multimerization, the central region that serves as a flexible linker,
and the C-terminal domain that binds DNA (51). It has been reported that H-NS binds
DNA in two ways, in cis, where it binds two different sites on the same DNA molecule,
or in trans in which it binds two different DNA molecules (52). It has recently been
suggested that DNA compaction by H-NS may result from the antagonistic effects of HNS binding to DNA in trans and cis configurations (52). While H-NS plays a role in
chromosome compaction, it is not an essential protein and deletion of the hns gene results
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in cells with an increased levels of resistance to antibiotics, antiseptics, dyes, and
detergents (53), making it an unlikely candidate for novel antibiotic design.

HU (Heat Unstable Protein)
HU is 9.5 kDa protein that binds preferentially to DNA that exists in a supercoiled
state (54). It is a heterodimer that consists of two subunits, HUα and HUβ, encoded by
the genes hupA and hupB, respectively (55). The heterodimers of HU bind to nicked,
cruciform, and gapped DNA with higher affinity than linear DNA (56, 57). Both the
homodimer of HUα2 and the heterodimer, HUαβ, bind to linear DNA with a greater
affinity (KD of 1,000 nM and
400 nM respectively) than the HUβ2 homodimer (KD = 29,000 nM) (58). The
experimentally determined crystal structure of HU indicates that it consists of three βstrands and three α-helices (Figure 2) (59). Deletion of both hupA and hupB genes from
E. coli alters a number of cellular processes including transposition, recombination,
replication, transcription, and chromosome condensation, resulting in poor growth, yet
neither gene is essential (60).
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Figure 1: The three-dimensional structure of the H-NS C-terminal domain.
The 47 residue structure was obtained from the hydrolysis of H-NS protein with bovine
trypsin (PDBID: 1HNR (61)). This structure was determined by NMR measurements and
-sheet (yellow), an
alpha-helix (red) and a 3(10)-helix, which form a hydrophobic core (red), stabilizing the
entire structure. This domain has been found to bind to DNA. The structure was rendered
in MOE version 2011.1.

Fis (Factor for Inversion Stimulation)
Fis is an 11.2 kDa protein that forms homodimers (Figure 3) (62). This protein
binds to DNA with no specificity and, depending on the sequence of the
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Figure 2: The solution structure of the HU protein from Bacillus stearothermophilus
(PDBID: 1HUE (59)). The alpha helices are shown in red and the beta strands are shown in
yellow. The structure was rendered in MOE version 2011.1.

DNA, it can induce 50°- 90° bends in the DNA upon binding (63, 64). It has been shown
to play roles in DNA inversion, gene regulation, and chromosome condensation (65-67).
When Fis binds to nicked plasmids, it increases the number of negative supercoils
trapped upon the ligation of the DNA molecule (64). The protein is present in large
amounts during the exponential phase of growth. However, the amount of Fis protein
drops to undetectable levels upon entry into stationary phase and recovery from
stationary phase results in a peak of Fis synthesis prior to the first round of cell division
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(68). To date no studies have shown that this protein is essential for cell growth, making
it an unlikely candidate for novel antibiotic design.

Figure 3: The X-Ray crystal structure of a Fis homodimer (residues 26-98) purified from E.
coli (PDB Code 1ETY) (69)). The red helices show the B and C helices (the BC turn) in Fis. The
figure was generated using MOE version 2011.1.

The Oligonucleotide Binding (OB) Fold Proteins in Eukaryotes and Prokaryotes
The OB fold proteins have been shown to play major roles in processes such as
DNA replication, recombination, repair, gene regulation, chromosome condensation and
telomere homeostasis (29, 70-73). These proteins were originally identified in both
bacteria and yeast (71). Many members of the OB-fold family establish protein-DNA,
protein-RNA, or protein-protein interactions (70, 74-81). However, their roles in ssDNA
interactions have been the most thoroughly characterized (72, 81).
13

OB-fold domains/proteins vary in length from 70-150 amino acids and the degree
of amino acid sequence identity is often low across species (72). In contrast, the OB-fold
domains/proteins share the same structural features of five antiparallel β-strands that form
a flattened β-barrel structure (82). The connecting loops between the β-strands vary in
length, sequence, and conformation, contributing to the binding specificities of these
proteins (81). OB fold motifs are often present as tandem repeats in proteins and protein
complexes suggesting that their interaction with ssDNA is in a cooperative fashion (81).
OB fold domains/proteins are found in both prokaryotic and eukaryotic cells (79,
83). Prokaryotes, in general, contain OB fold proteins and not the larger proteins that
contain OB domains. In higher eukaryotes, the OB-fold domain is part of a very large
family of transcription factors known as Y-box proteins (84-86). Two of the most studied
proteins in this category are TPP1, which is a telomere-related protein, and RAP70,
which functions in the repair of DNA double stranded breaks (79, 87-91).

The Cold Shock Related Proteins
The Csp (Cold Shock Related Proteins) in bacteria are small OB fold proteins
present in many bacterial species. E. coli K12 encodes nine csp genes, labeled cspA
through cspI. Two of the Csp proteins, CspC and CspE, have been shown to play a role
in maintenance of chromosome structure (39). The polypeptides made from these genes
share between 29 and 83 percent identity and 46 to 91 percent similarity in their amino
acid sequences, with half of the pairwise comparisons having over 70% amino acid
similarity (70). CspA and CspB share 80% amino acid identity, CspC and CspE share
83% identity, CspF and CspH share 77% identity, and CspG and CspI are 79% identical
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(92). Where it has been investigated, these sets of Csp protein pairs are regulated
similarly and, in the case of CspC and CspE, have similar biological functions (39, 93).
CspD is the least similar to any of the other Csp proteins and is also regulated in a unique
manner (94). Overexpression of cspD from a plasmid vector is lethal, a phenotype unique
to CspD (95).
In vivo and in vitro studies of the cold shock-related proteins have described a
number of functions for different Csp proteins, including the maintenance of
chromosome folding and the low level regulation of several bacterial genes (29, 93, 9698). The majority of these functions are related to the ability of Csp proteins to bind
single-stranded nucleic acids in a sequence specific manner (70, 99-101).

CspA
CspA (Ec) was the first protein to be identified as being induced upon
temperature downshift, using a comparison of 2-D gels from cells growth at 37ºC and
cold-shocked cells (102). The gene maps to 80.1 minutes on the E. coli chromosome and
the cspA gene is monocistronic (Figure 4). During temperature
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Figure 4: The chromosomal positions of the nine csp genes in E. coli K12. Blue
arrows indicate the direction of gene transcription. Of the nine csp genes, only cspE is in
an operon. cspG and cspH are located next to each other but are divergently transcribed.
cspB and cspF are also divergently transcribed and are located close to cspI.

downshift (37ºC to 15ºC), cell growth and proliferation is inhibited and changes in
protein expression patterns occur with most cellular protein synthesis being inhibited
(103). While it has been reported that CspA production can reach levels of 100 μM
within 1-1.5 hours after temperature downshift (102), later studies contradicted these
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findings and large amounts of CspA were documented under non-stress conditions as
well (104).
The 5’ end of the cspA mRNA contains a 159 base untranslated region (UTR)
(102). Overproduction of just the first 142 bases of the UTR decreases cspA expression at
low temperatures (102). When both the 5’ UTR and cspA are overexpressed from a
pBR322 derived plasmid (30-50 copies per cell), CspA protein concentrations returns to
wild type levels implying that CspA regulates its own expression (84).
Of the nine Csp proteins in E. coli K12, only CspA (Ec), has a solved crystal
structure (105) (Figure 5A). CspA (Ec) exists as a monomer in both a crystal and a
solution and the structure of CspA (Ec) is an OB-fold containing the characteristic five
antiparallel beta strands that form a beta barrel (105, 106).

CspB
The cspB gene was discovered through Southern blot analysis using cspA as a
probe (107). This gene maps to 35.3 minutes on the E. coli K12 chromosome (Figure 4)
and it is monocistronic. CspB (Ec) has been reported to be induced upon temperature
downshift. Gene regulation experiments using a cspB-lacZ gene fusion show that a shift
of exponentially growing cells from 37°C to 15°C results in an approximately 17 fold
increase of induction of lacZ (107). These data suggests that cspB is a cold inducible
gene. The in vivo functions of CspB have yet to be identified and there are no
experimentally determined structures for this protein.
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A

B
Figure 5 The experimentally determined structures of CspA (Ec). A) The yellow
ribbon shows the protein backbone structure of CspA from E. coli K12 as determined by X-ray
crystallography (PDBID:1MJC) (105). B) The NMR structure of CspA (Ec) (PDBID:3MEF)
(106). The pink ribbon shows the backbone structure of the CspA from E.coli K12 as determined
by NMR spectroscopy. The figures were generated using MOE version 2011.1.
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CspC
The cspC gene was identified via Southern blot using cspA as a probe and it is
monocistronic (107). This gene maps to 41.0 minutes on the bacterial chromosome
(Figure 4). The expression patterns of cspC were determined using a cspC-lacZ fusion
and has been shown to be constitutively expressed in the bacterial cell. Overexpression of
the cspC gene increases the expression of 4 genes upsA, osmY, dps, and rpoS, through
increasing the stability of their mRNAs (93). UpsA is a protein that responds to numerous
stresses. RpoS is a sigma factor used for global stress response. RpoS is a regulator of
osmY, which encodes a periplasmic protein of E. coli. Dps is a non-specific DNA-binding
protein abundant in starved E. coli cells and has been shown to be important for
resistance to hydrogen peroxide (108-110).
The CspC (Ec) protein has been functionally identified as a multicopy suppressor
of mutations in the mukB gene (111). Point mutations in mukB have several phenotypes,
including a 1000-fold increase in anucleate bacterial cells and the inability to grow above
30°C (111). The overexpression of the cspC gene from a plasmid vector has been shown
to reverse both of these phenotypes (111). The protein product, CspC (Ec), has also been
shown to bind nucleic acids (93). SELEX experiments with CspC demonstrate binding to
an 88 nucleotide ssDNA probe that contains the consensus sequence AGGGAGGGA and
to the complementary sequence with a lesser affinity, similar to CspB (Ec) (76).
However, CspC (Ec) reportedly will not bind to a 45-nucleotide ssDNA molecule
containing three tandem repeats of the consensus sequence (76). The SELEX technique
has previously identified suboptimal binding sequences for CspA and CspE (70). There
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are no experimentally determined structures for this protein and the binding
characteristics have not been investigated by any other techniques.

CspD
The cspD gene was identified through sequencing the upstream region of clpA
(112). This gene maps to 19.9 minutes on the E. coli K12 chromosome (Figure 4). It is
monocistronic and cspD-lacZ fusion studies have shown that expression is reduced
during cold shock (80) and increased in slow growing cells (113). Studies of CspD (Ec)
show that it is induced during nutritional starvation/stationary phase (95, 111, 114,
115). CspD (Ec) exists as a dimer in solution and binds ssDNA (95). The binding of
ssDNA by CspD (Ec) was investigated through electron microscopy showing that CspD
(Ec) does not coat the DNA. Instead the DNA-CspD (Ec) forms complexes that resemble
ball-like structures (95). It has been shown that CspD (Ec) acts as a replication inhibitor
through its DNA binding to the oriC region of the chromosome (95). The overexpression
of CspD (Ec) from a plasmid vector is a lethal event and recent studies show that CspD
(Ec) is a target for degradation by the AAA+ protease Lon (94).
Cells that have cspD deleted are still viable. However, the loss or increase of
CspD expression results in either a decrease or increase, respectively, in persister cell
formation (116). Persister cells are a small subpopulation of specialized dormant cells
that are resistant to antibiotic treatment. Formation of persister cells occurs stochastically
and is deterministically increased when cells enter stationary phase (117). There are no
experimentally determined structures for CspD(Ec).
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CspE
The cspE gene is the only csp that is part of an operon. The crcB gene is located
downstream of cspE and there is one predicted promoter for both genes (39). The gene
maps to 14.1 minutes on the E. coli K12 chromosome (Figure 4) (39). The cspE gene is
constitutively expressed and in cells that have cspA deleted the level of cspE expression
increased 1.5-fold following cold shock (114).
The gene product of cspE, CspE (Ec), is a 6.3 (kDa) protein that is stable in cells
that have the Lon protease deleted (118). These data suggest that CspE protein levels
could be regulated in the cell by cellular proteases. The DNA binding preference for
CspE (Ec) has been identified as a stretch of single stranded DNA containing at least 6
thymidine residues, in an 8 base sequence and CspE has been shown to form dimers in
solution (70).
Camphor vapors are lethal to cells because they decondense the
chromosome. While the size and shape of the cell does not change, the DNA
decondenses to fill the entire cytoplasm. The overexpression of CspE from a plasmid
vector leads to both camphor resistance and suppresses the phenotypes of deletions in the
mukB gene (39). The overexpression of cspE can suppress both the production of
anucleate cells and the temperature-sensitive colony formation phenotypes of mukB
mutations (111). To examine if the overexpression of cspE increases the amount of the
mutant MukB protein produced, a mukB-lacZ transcriptional fusion strain was examined.
The overexpression of cspE did not increase the transcription of mukB (84). CspE
suppresses a deletion of mukB, indicating that it must substitute for the function(s) of
MukB. Since camphor decondenses the chromosome both in vivo and in vitro, both of
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these studies suggest CspE (Ec) plays a role in chromosome condensation. However, the
exact mechanisms by which CspE directly or indirectly reverses these conditions have
not been identified.
CspE (Ec) shows some regulation of rcsA, which in turn regulates capsule
synthesis, and of rpoS, which is the stress response sigma factor (93). CspE has also been
shown to increase the production of UspA (universal stress protein), OsmY (osmoticallyinduced protein) and Dps (DNA protection during starvation) (93). Exactly how CspE
functions in the regulation of these genes is also not known.
Recently, it has been reported that CspE is regulated by cyclic AMP Receptor
Protein (CRP) through a putative target site located at -61 upstream from the transcription
start site of CspE (119). Studies using a strain containing a deletion of crp led to growth
defects at low temperatures indicating that CRP may play an important role in cold
acclimation (119). There are no experimentally determined structures for CspE.

CspF and H
A search of the E. coli K12 genome using BLAST and cspE as bait led to the
identification of the genes cspF and cspH (113, 120). cspF maps to 35.3 minutes and
cspH maps to 20.6 minutes on the E. coli K12 chromosome (Figure 4) (113). The cspF
and cspH genes are monocistronic. While these genes have been identified, very little is
known about them or their protein products. The induction patterns of cspF (Ec) and
cspH (Ec) have not been elucidated nor have the functions of the proteins that are
transcribed from these genes. There are no experimentally solved structures for the CspF
and CspH.
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CspG
The cspG gene is induced upon temperature downshift, is monocistronic and
contains a 5’ untranslated region (UTR) (121, 122). The gene maps to 35.3 minutes on
the E. coli K12 chromosome (Figure 4). Studies searching for promoters that are induced
by cold temperatures (expressed at 15C but not expressed at 37C) identified the
promoter of the cspG gene (121). The expression of cspG was examined using a cspGlacZ fusion, confirming that cspG is induced at lower temperatures (121). An analysis of
cspG showed that, similar to cspA, the cspG transcript contains a large 5’ UTR region
(121, 122). The biological functions for CspG have not yet been identified and there are
no experimentally determined structures for the protein.

CspI
A search of the complete genome of E. coli K12, using cspA as the bait for
additional csp-related sequences, identified cspI (113). This gene maps to 35.3 minutes
on the E. coli K12 chromosome (Figure 4). Studies of cspI-lacZ gene fusions show that
cspI expression is induced approximately 8-fold during a shift in temperature from 37C
to 15C. The mRNA of cspI contains a 5’ UTR which has been determined to contain a
“cold box” sequence (115). As of yet, no biological functions for this gene product have
been identified and there is no solved crystal structure for this protein.
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The Csp proteins in Bacillus subtilis
Bacillus subtilis has three Csp homologues and they share greater than 70%
amino acid identity to CspE of E.coli K12. In B. subtilis, the proteins are known as CspB
(Bs), CspC (Bs), and CspD (Bs) (123, 124). Deletion studies in B. subtilis show that at
least one of the csp genes is required for cell viability, with no preference as to which csp
remains (123). Thus, the csp genes comprise an essential family of genes, at least in this
bacterium.
CspB (Bs) and CspE (Ec) have optimal binding to the same DNA sequence of at
least 6 dT residues in an 8 base single stranded DNA molecule (70, 99, 125). The
proteins bind to RNA molecules, but fail to bind to double-stranded DNA. It has
previously been determined that six aromatic residues (Trp8, Phe15, Phe17, Phe27, Phe30,
and Phe38) and five positively charged amino acid residues (Lys7, Lys13, His29, Lys39 and
Arg56) are involved in binding of CspB (Bs) to single-stranded DNA (ssDNA) (126). The
amino acid residues responsible for ssDNA binding are arranged on one side of the
surface of the protein and form the nucleic acid binding interface (127).
Studies show that in vitro, upon binding to ssDNA, CspB (Bs) is protected from
degradation by trypsin, suggesting that the protein levels could be regulated in the cell by
cellular proteases (128, 129). If the protein is unstable in vivo, then unbound cytoplasmic
protein should be subject to degradation. CspB (Bs) contains a single surface exposed
tryptophan whose fluorescence is quenched when ssDNA binds to the protein (99).
Of the three Csp proteins in B. subtilis, one protein, CspB (Bs) has a solved
crystal structure, both with and without its ssDNA ligand (126). The crystal and NMR
structures of CspB (Bs) show that the backbone is an OB-fold protein containing the
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typical five antiparallel β strands that form the flattened β-barrel structure (Figure 6)
(130). The structures of the Csps in B. subtilis have been analyzed via Circular Dichroism
(CD) spectroscopy (129). When subjected to this method of analysis, the three
homologues display very similar signals with a characteristic broad peak at ~ 220 nm and
a sharp peak at ~ 190 nm, in the near UV spectrum (Figure 7). This signal is
characteristic of the five antiparallel β strands that form an OB-fold structure. Denatured
Csp protein appears as a line that descends past the X-axis (Figure 7). Other bacterial
species, including Bacillus caldolyticus and Thermotoga maritime, have solved Csp
structures, all of which have been shown to be OB-fold proteins (131-133).

25

A

B
Figure 6: Protein backbone overlay of the crystal and NMR structures of CspB from B.
subtilis(PDB ID: 1CSP) (PDB ID: 1NMF). A) The single amino acid residue in stick form is an
exposed tryptophan residue whose fluorescence is quenched when bound by ssDNA (134). B)
The crystal structure of CspB (Bs) bound to poly (dT)6 (PDB:ID2ES2) showing the hydrophobic
and hydrophilic surfaces of the protein. The green, pink, and white areas indicate hydrophobic,
hydrophilic and neutral surfaces of the protein, respectfully. The residues Trp8, Phe15, Phe17,
Phe27, Phe30, and Phe38 form the green hydrophobic patch that is involved in binding of CspB (Bs)
to single-stranded DNA (ssDNA) (126). The model was generated using MOE version 2011.1

26

Figure 7: The near and far UV spectrum of the three Csps in B. subtilis as determined by
CD spectroscopy. The proteins display the characteristic broad peak at 220 nm and a sharp peak
at 190 nm in the near UV spectrum (A) and broad peak from 250 nm to 290 nm at the far UV
spectrum (B) (129). The three Csp proteins, CspB (solid line), CspC (dashed line) and CspD
(alternating dashed and dotted line) all show display this characteristic CD signal. The denatured
Csp protein in B. subtilis is characterized by a sharp drop in the signal (dotted line). This figure
was reused with permission by the author (129).

The OB-fold proteins are found in both prokaryotic and eukaryotic cells. Since I
am targeting the Csps for inhibition an examination of the most studied prokaryotic OBfolds must also be considered. Next I will examine the eukaryotic OB-folds to determine
whether they are similar enough to be affected by the same small molecule that will
target the Csps.

TPP1
A protein complex called sheltrin protects the telomeres of humans. This is a six
component protein complex formed by TRF1, TRF2, RAP1, TIN2, TPP1 and POT1
(135). TPP1 (Figure 8) and POT1 (Figure 9) form a stable ssDNA-binding complex (8991). A number of studies have shown that the DNA binding
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Figure 8: The crystal structure of human TPP1 (PDBID:2I46). The beta barrel structures are
shown in yellow ribbons and the alpha helices are in red (90). The structure was rendered using
MOE version 2011.1.
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Figure 9: The crystal structure of human POT1 The protein is made up of a beta barrel
structure (yellow ribbon) and alpha helices (red ribbon) bound to telomeric single-stranded DNA
(red and blue stick figure) (PDBID:1XJV) (136). The structure was rendered using MOE version
2011.1.

function of TOP1 is enhanced by the binding of TPP1 to POT1 (90, 91). While TPP1 has
been shown to contain an OB fold domain near its N-terminus, this protein is unable to
bind ssDNA in the absence of TOP1 (89-91). However, it has been demonstrated that the
OB domain of TPP1 is a key player in the recruitment of telomerase (89-91).

RPA
The ssDNA binding ability of RPA (replication protein A) has been well
characterized (87, 88). This complex is heterotrimeric consisting of three subunits of
70.0, 32.0, and 14.0 kDa. The binding of ssDNA is mediated by a set of OB folds
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referred to as DBD-A, -B, -C, and –D. The DBD-A, -B and -C domains are in the
RPA70 subunit (Figure 10) (78, 79, 137, 138).

Figure 10: The Crystal structure of Human RPA70 (PDBID:2B29) (138). The RPA70 subunit
contains two alpha helices (red ribbon) and eight beta strands (yellow ribbon) that form the beta
barrel structure. This figure was generated using MOE version 2011.1.

After a double-strand break occurs, sections of DNA around the 5' ends of the
break are cut away in a process called resection. RPA is initially bound to the ssDNA
generated by resection and is frequently used as a cytological marker for DNA end
processing making the DNA ends compatible for ligation in vivo (139-141) Furthermore,
RPA-bound ssDNA recruits the Mec1-Ddc2 complex (ATR-ATRIP in human) for
activation of the DNA damage checkpoint in response to double stranded breaks (80).
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The prokaryotic and eukaryotic OB-folds share the same over all structure and
function of binding to nucleic acids (72). An amino acid sequence analysis of the Csps,
TPP1, and RPA shows that there significant differences between the sequences (data not
shown). Likewise the superimposition of CspE (Ec) and TPP1 and RPA resulted in very
high RMSD scores indicating significant differences in structure (data not shown). This is
consistent with the literature reports that while the OB-folds share over all structure and
function their sequences and size vary across species. Taken together these data allowed
me to conclude that the Csps can be utilized for computational drug discovery.

Computational Drug Discovery
Computational drug discovery is an effective method for the detection of specific
protein inhibitors (142). It is widely used because it is an economical and rapid process in
drug development (142). The process involves the use of computational tools, such as
sequence analysis, homology modeling, and virtual screening. Collectively, these data are
then used to predict the structures and functions of proteins and screen large libraries of
small molecules to predict sites of inhibitory binding (143).
The sequence analysis is the first step in the process and begins with choosing a
well-studied homologue of the protein of interest to serve as a template for building a
computationally predicted homology model. If the specific protein of interest has not
been studied, a closely related homologue that has been studied is used for building a
computationally predicted homology model of the protein of interest. Using
computational alignment software, I can analyze the amino acid sequences of both
proteins (the protein of interest and the related, well-studied homologue) to determine
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their similarity and identity (144-146). The homologues should share at least 29% amino
acid identity with the protein of interest and experimentally solved structures through xray crystallography or nuclear magnetic resonance (NMR) of the template should be
available (146). Once this homologue has been identified, it can then be used as a
template to predict and model the three-dimensional structure of the protein of interest
(146).
The method of homology modeling predicts the three dimensional structure of a
protein based primarily on its amino acid sequence similarity to one or more proteins
with experimentally determined crystal or NMR structures (146, 147). These models are
considered accurate if they have a Root Mean Square Deviation (RMSD) of less than 2 Å
(148-150). Using this method involves identifying a homologue of known structure,
aligning the amino acid sequences, building the model based on the alignment, and
assessing and refining the model. The use of a homologue of known structure with
greater than 40% amino acid identity usually results in 90% accuracy of the main chain
atoms, resulting in an RMSD of approximately 1 Å (147). Three-dimensional models of
the Csp like protein in Psychrobacter sp. B6 have been successfully generated using this
method (151).
Once an accurate model of the protein of interest has been generated the
computational model can be analyzed for binding sites (142). These data can be used to
predict sites on the protein of interest that may serve as potential targets for small
molecules. This method has been successful in the development of potential drugs for
targeting GPCR proteins and Cyclophilin D (152, 153).
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HYPOTHESIS & RESEARCH GOALS
Given that the Csp proteins are present in the majority of bacterial genomes, where it has
been studied they are essential for viability and there are crystal and NMR structures for
several of the Csp proteins, I have formulated the following hypotheses.
1) If CspE (Ec) is functionally and structurally similar to CspB (Bs) then CspE (Ec)
should have a similar structure and be protected from proteolysis by binding ssDNA.

2) If CspE (Ec) is functionally and structurally similar to CspB (Bs) then I can use CspB
(Bs) as template to build an accurate homology model of CspE (Ec).

3) If the Csps are essential proteins then small molecule screening and docking
simulations should allow me to find a molecular inhibitor of Csp function and cell growth
in E. coli K12.

I will test these hypotheses using the following research goals.

1) I will characterize the structure and function of the CspE (Ec) protein using CspB (Bs)
as a template.

2) I will use the solved crystal structures of CspB (Bs) to build an accurate computational
model of CspE (Ec).

3) I will use structural, biochemical, computational and protein variant data on CspE (Ec)
to predict sites of small molecule inhibition and impact cell growth.
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Significance of Research
This work will demonstrate the feasibility of using molecular modeling to
accurately predict which amino acid changes in the CspE protein will result in loss of
function and structure. Prior to molecular modeling, amino acid changes in the protein
were studied through random mutagenesis of the DNA sequence of the gene, leading to
the serendipitous discovery of a phenotype. With the use of molecular modeling, I can
build a model of the protein, study the resulting model structure, and use that information
to predict binding pockets and amino acids that function in maintaining structure and
function. Use of this information should allow me to select features of the protein that can
be exploited for small molecule screening and docking simulations of CspE and its
homologues.

My dissertation will examine the plausibility of screening large libraries of
commercially available compounds for antimicrobial activities using novel, specific
cellular targets to determine drug design. I will generate and examine a computational
model of CspE, as well as the functional properties of CspE and variants of this protein
with single amino acid changes to determine structure-function correlations that can be
exploited as targets for inhibitor molecules.

Structure-function studies investigating the stability of CspE through protease
degradation assays of wild type CspE and its variants will allow me to determine whether
single amino acid changes render the CspE (Ec) protein more or less susceptible to
degradation. I will examine the variant proteins for any structural change through
Circular Dichroism Spectroscopy. The information on the variants will complement
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existing in vivo and in vitro data, allowing the classification of the protein variants based
on their impact on gene regulation, ssDNA binding, dimer formation, camphor resistance,
protein structure and protein stability.

Since there is no crystal structure for CspE (Ec), I have used the structure of CspB
(Bs) to build a computational model of CspE, using the Molecular Operating
Environment (MOE) software. I will use this model to characterize the structure and
function of CspE (Ec) in silico and screen databases of lead-like compounds for those
that may bind to and inhibit the functions of CspE (Ec). The inhibitory effects of any
identified compound on E. coli K12 will be quantified using in vivo assays.
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METHODS & MATERIALS
Protein Induction and Purification.
Wild type CspE
E. coli BL21 (DE3) pLysS cells containing pCH1 (pET9a containing cspE from
the AUG start codon to 12 bp downstream of the TAA stop codon, in between the NdeI
and BamHI restriction sites) was used to induce large scale production of wild type CspE
(70). Overnight cultures were inoculated from frozen glycerol stocks. Cells were grown
in 5 mL of LB with 34 mg/mL chloramphenicol and 30 mg/mL kanamycin at 37 C
overnight, with aeration. The culture was added to 500 mL of LB with 34 mg/mL
chloramphenicol and 30 mg/mL kanamycin (prewarmed to 37 C). Cultures were grown
in a 37 C water bath, with shaking, at 190 rpm to an OD600 =0.6, after which CspE
protein synthesis was induced with 1 mM IPTG. Cultures were incubated overnight.
Cells were pelleted by centrifuging for 30 minutes at 4,000 x g at 4 C. The cell
pellets were resuspended in Buffer A (300 mM NaCl 20 mM) Tris-HCl pH 8.5, 1 mM
EDTA, and 10% glycerol). The cells lysed by passing through a French press 3 times at
15,000 PSI. DNA was precipitated through the addition of polyethylenimine (PEI) to a
final concentration of 0.01%. PEI was added slowly over 60 minutes at 4C with stirring.
Stirring continued for an additional 20 minutes and the DNA was pelleted by
centrifugation at 27,000 x g for 30 minutes at 4C to produce a clarified lysate containing
CspE.
The clarified lysate was dialyzed overnight into modified Buffer A without NaCl
at 4C. The dialyzed samples were applied to a Q-Sepharose Fast Flow column (GE
Healthcare Piscataway, NJ). The column was equilibrated with Buffer A at 4C, the
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dialyzed lysate was loaded onto the column at a flow rate of 1 mL per minute, and
washed with 1.5 times the column volume of Buffer A. Two-milliliter fractions were
collected at a flow rate of 1 mL per minute. Fractions were analyzed via SDS-PAGE
(10% Bis-Tris gels) in MES Buffer with Coomassie blue R250 staining. Fractions
containing the CspE protein were pooled, the pH was lowered to 7.5 by the addition of 1
M HCl and loaded onto an SP-sepharose column (GE Healthcare, Piscataway, NJ). For
SP-Sepharose ion exchange chromatography, the column was equilibrated with Buffer B
(20 mM Tris-HCl pH 7.5, 1 mM EDTA, and 10% glycerol) at 4C. The pH adjusted QSepharose fractions were applied and the column was washed with 1.5 column volumes
of Buffer B at a flow rate of 1 mL per minute. Fractions containing the CspE were pooled
and dialyzed overnight against 500 mL Buffer C (20 mM MES pH 5.5, 1 mM EDTA, and
10% glycerol). CspE protein does not bind to either of these columns: it eluted from the
column in the void volume.
The dialyzed lysate was adjusted to 3 M NaCl and applied onto a pre-equilibrated
(in Buffer C with 3 mM NaCl) Phenyl-Sepharose High Performance column (GE
Healthcare, Piscataway, NJ) at 4C, with a flow rate of 1 mL per minute. CspE binds to
this column matrix. The column was washed with 1.5 column volumes of Buffer C
containing 3 mM NaCl. The CspE protein was eluted from the column by a linear salt
gradient from 3 mM to 600 mM NaCl in Buffer C, then the column was washed with 1.5
column volumes of Buffer C. Fractions containing the CspE protein were pooled and
concentrated using a 0.05% Triton X-100 pre-treated Vivaspin® concentrator (MWCO 5
000, Sartorius Edgewood, NY) at 1,500 x g at 4C until a volume of 5-10% of the sizeexclusion was reached (<10 mL). The concentrated fractions and Vivaspin® flow
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through were analyzed via SDS-PAGE (10% Bis-Tris gels in MES buffer) to confirm the
presence of CspE and its variants.
The concentrated fractions were dialyzed into Buffer B and applied to a 110 mL,
63 cm X 1.5 cm Sephacryl S-100 sizing column (GE Healthcare, Piscataway, NJ). The
column was washed with 2 column volumes of Buffer B at a flow rate of 2 mL/min. The
first 40 mL of void volume were collected as a bolus, the next ~100 mL were collected as
~1 mL fractions. The last 10 mL were collected as a bolus. SDS PAGE identified the
fractions containing CspE and the purity of the fractions containing CspE was determined
to be greater than 90 % by SDS-PAGE (10% Bis-Tris gels) in MES Buffer with
Coomassie staining and densitometric analysis via Quantity 1 densitometry software
(Bio-Rad, Hercules, CA) using a GS-800 scanner (Bio-Rad, Hercules, CA). The
concentration of CspE was determined spectrophotometrically with a Jenway 6315
UV/Visible Spectrophotometer (Jenway, Staffordshire, UK) using the calculated
extinction coefficient ε280 = 5690 L mol-1 cm-1 and the calculated molecular weight of
CspE is 6,336 Da.
The proteins were analyzed for ssDNA binding ability through tryptophan
fluorescence quenching using a Fluoromax-3® fluorimeter (Horiba Scientific, Edison,
NJ) with an excitation wavelength of 292 nm and an emission scan from 312 nm-450 nm.
Fluorescence at 349 nm was recorded. Binding assays were repeated a minimum of 3
times data shown includes plus and minus the standard deviations were calculated. These
data points were compared to the previous results obtained by Danielle Johnson (92).
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Variants of CspE (Ec)
Previously, single point mutations (resulting in the codon changes: I4E, K9E,
V29M, A45P, K59E) in wild type cspE (Ec) were generated by C. Tavano and O. Sand
using either the Quick Change® Site Directed Mutagenesis Kit (Stratagene; La Jolla,
CA) with the pCH1 plasmid or in a screen for regulation deficient mutants using a pBAD
derivative containing cspE (N. Trun, personal communication). The codon changes are
named with the single amino acid code for wild type amino acid listed first - the position
of the amino acid - the replaced amino acid (for example in I4E the isoleucine at position
4 of wild type CspE (Ec) was replaced with glutamic acid). The coding region for all of
the mutations were subsequently cloned into the T7 expression vector pET9a (the
backbone of pCH1). The protein containing a sixth amino acid change, K59R, was
generated for this study by changing the DNA sequence in the pCH1 plasmid containing
wild type CspE with the QuickChange II® mutagenesis kit (Stratagene, La Jolla, CA).
The plasmids were transformed into the E. coli strain BL21 (λDE3) pLysS to
generate an overexpression strain. Strains containing the I4E, K59E, V29M, A45P, K59R
or K9E mutant genes were used. The protein variants from the mutant genes were
purified the same as described for the wild type CspE (Ec) protein, with one exception.
The protein containing the amino acid change A45P was eluted from the Q-Sepharose
column by applying 1.5 column volumes of Buffer A containing 1 M NaCl. The elution
volume containing A45P was dialyzed against Buffer C and the remaining purification
was carried out as for WT CspE (Ec).
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Nucleic Acids
The synthetic oligonucleotides were purchased as HPLC-purified molecules from
IDT-DNA (Coralville, IA).
The Poly (dT) 15 sequence is 5’ TTT TTT TTT TTT TTT 3’, the K59R Forward primer5’ AAC GGT GCC AGA GGC CCT TCT GCT G 3’ and the K59R Reverse primer
primer 5’ CCT CTG GCA CCG TTA GTG A 3’

Protein Degradation Assays
Degradation assays were carried out at 37C in buffer containing 20 mM TrisHCl pH 7.5, 0.5 mM EDTA, and 100 mM KCl. Three different aliquots of 125 μl
contained either (1) 40 μM protein alone, (2) 3 μM trypsin plus 40 μM protein, (3) 3μM
trypsin, 40 μM ssDNA and 40 μM protein. Sixteen microliter aliquots were removed at 0,
4, 15, 30 and 60-minute time points. The aliquots were analyzed via SDS- PAGE
electrophoresis in 10% Bis-Tris polyacrylamide gels. Gels were stained with Coomassie
blue R-250 and analyzed via Quantity 1 densitometry software using a BioRad® GS-800
scanner.

Disk Diffusion Analysis of Lead Compounds
E.coli K12 strain MG1655 was grown overnight in 5 mL of M63 minimal medium
supplemented with 0.2% glucose (154). Fifty microliters of the overnight culture were
added to 3 mL of molten M63 top agar and poured onto M63 minimal agar plates
containing 0.2% glucose. After the top agar solidified, sterile 5mm filter paper disks were
placed on top of the agar and 10 μl of the compound in concentrations of 0.10 mM, 10
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mM, 50 mM, and 100 mM were added to the disks, one concentration per disk. As a
control, 10 μl of the diluent (10% propanol) was also used. Plates were kept at room
temperature for 10 minutes to dry and were incubated overnight at 37C. The diameters
of zones of inhibition were measured in millimeters (mm). Assays were repeated 3 times.
Circular Dichroism Spectroscopy
CD spectroscopy was carried out using a Jasco® CD spectroscopy analyzer
(Jasco, Easton MD). Protein concentrations were 40 μM in buffer containing 20 mM
potassium phosphate, pH 7.4. Sample temperature was maintained at 25C during the
scan. Each protein sample was scanned a total of 3 times and data were averaged. Data
were smoothed using the bundled software that accompanies the spectrometer.

Sequence Data and Analysis
All in silico work was carried out using the Molecular Operating Environment
(MOE) version 2009.10 and 2010.10. software (Windows and Mac OS X platforms) from
the Chemical Computing Group (www.chemcomp.com). The sequences used to build the
homology models were generated as FASTA formatted files and loaded into
MOE. Sequence alignments were carried out using the “Align” option in MOE. The
alignment was color-coded using TeXshade (www.ctan.org).

Homology Modeling
The models were generated using the “Homology Build” feature in MOE
(2009.10), applying the AMBER99 force field that is used to minimize the bond
stretching energies of the molecules. Homology modeling was carried out using the
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solved crystal structure of CspB (PDB ID: 1CSP) from B. subtilis as the template to
generate virtual structures the Csp proteins of E. coli K12.

Surface Calculations
The atoms of the Csp homology models were protonated and partial charges were
added using the “Protonate 3D” and “Partial Charges” parameters in MOE. Surface
calculations were carried out using the “Surfaces and Maps” option.

Binding Site Analysis of CspE (Ec)
Three 140 μl reactions containing 1 μM of CspE (Ec) wild type protein, I4E
protein or K9E protein were incubated for 5 minutes at room temperature with 1 μM of
poly (dT)15 ssDNA at a ratio of 1:1 (protein:DNA) in buffer containing 20 mM Tris-HCl
pH 7.5, 0.5 mM EDTA, and 100 mM KCl. Tryptophan fluorescence was monitored on a
Horiba Scientific Fluoromax-3® fluorimeter with an excitation wavelength of 292 nm
and an emission scan from 312 nm-420 nm. Fluorescence at 349 nm was recorded.
Binding assays were repeated a minimum of 3 times and the standard errors (S.E.) were
determined. Fluorescence titrations were performed as individual reactions.
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RESULTS
Molecular Modeling
The alignment of the nine Csp protein sequences from E. coli K12 with CspB
from B. subtilis was carried out via MOE (Figure 11). TeXshade analysis of this
alignment shows the conserved residues of the ten amino acid chains (Figure 11). To
confirm accuracy of this approach, a computationally rendered model of CspA (Ec) was
superimposed with the experimentally determined crystal structure of CspA (Ec)
(PDBID: JM1C) (Figure 12). The computational analysis of the superimposition resulted
in an (Root Mean Square Deviation) RMSD of 2.3 Å. This indicates that the differences
between the positions of the atoms in the predicted model versus the position of the
atoms of experimentally determined crystal structure are 2.3 Å apart. Even though this
value is slightly above the acceptable value of 2 Å (148-150), this low RMSD value
indicates that accurate computational models of the Csps can be generated. Using the
determined alignment, the nine Csps (Ec) were modeled using the crystal structure of
CspB (Bs) as the template. Superimposing the ten proteins resulted in highly similar
protein backbone structures among the 10 Csp proteins with a RMSD of 1.01 Å (Figure
13).
The electrostatic surface analysis of the nine computationally predicted models
shows that there is fairly even distribution of positive and negative
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Figure 11: The Alignment of the 9 Csps from E. coli and CspB from Bacillus subtilis.
Residues boxed in green are responsible for DNA binding in CspB in Bacillus subtilis (128). The
-strand are indicated above the alignment.
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A

B
Figure 12: A) The superimposed ribbon structures of the crystal structure CspA (Ec)
(yellow ribbon) (PDBID:JMIC) and the computationally generated model of CspA (Ec)
(blue ribbon). The calculated RMSD for the two structures is 2.3 Å. The model was generated
using MOE version 2011.1. B) The model of CspE (Ec) showing the position of the single point
amino acid substitutions in ball and stick form. I4E (yellow), K9E (red), V29M (purple), A45P
(green) and K59E/K59R (blue). This figure was generated using MOE version 2011.1
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Figure 13: The protein backbone overlay of the nine E. coli Csp proteins modeled and CspB
in B. subtilis (PDBID: 1CSP). The single amino acid residue that is highlighted is the tryptophan
residue that has been shown to be involved in DNA binding. The RMSD of the ten proteins over
each other is 1.040 Å. This figure was generated using MOE version 2011.1.
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Figure 14: The protein electrostatic surface map of the nine Csp proteins in E. coli modeled
using the crystal structure of CspB in B. subtilis (PDBID: 1CSP). The red, blue and white
areas indicate negative, positive and neutral areas of the protein surface based on solvation
analysis, respectively. The circles on CspF, -G, and –H indicate where the positive extension
from an arginine residue is located. This is extension is not present in the remaining 6 Csp
proteins. These figures were generated using MOE version 2011.1
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charges on the surface of the proteins (Figure 14). These data suggest an explanation for
why CspE does not bind to either an anion or a cation column during purification (see
methods and materials purification). Given the small size the proteins and the even
distribution of charges across the surface of the proteins, binding in a column milieu may
be unlikely. A hydrophobic surface analyses shows that there are distinct differences in
the surfaces of the nine proteins (Figure 15). With the exception of CspF and CspH, all of
the proteins display isolated focal point of hydrophobic amino acids that are produced by
the hydrophobic amino acids responsible for nucleic acid binding (Figure 15) (128).
These are indicated in Figure 15 as the green patches on each of the proteins. Neither
CspF nor CspH have substantial hydrophobic patches. There are no experimental data on
DNA binding by these proteins but I would predict that they have no or decreased
binding to nucleic acids.
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Figure 15: The hydrophobic surface analysis of the nine Csp models. The green, pink, and
white areas indicate hydrophobic, hydrophilic and neutral surfaces of the proteins, respectively.
The circles on CspF and –H indicate the missing hydrophobic patch that is present on the
remaining models. These figures were generated using MOE version 2011.1.
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Analysis of CspE and Variant Proteins
Using both a genetic screen for changes in gene regulation and in vitro site
directed mutagenesis, a collection of mutations in cspE (Ec) were isolated or constructed.
The mutations I4E (isoleucine at position 4 changed to a glutamic acid), K9E, V29M,
A45P and K59E were chosen for this study (see below) (Figure 12 B). Using the
molecular model of CspE (Ec) to predict structure-function correlations, the variant CspE
(Ec) proteins I4E, K9E, V29M, A45P, AND K59E were analyzed in MOE. The sequence
analysis of CspE (Ec) shows that only K9E and K59E align with the residues responsible
for DNA binding in CspB (Bs) (Figure 11) (99). The remaining proteins I4E, V29M, and
A45P are not in the predicted DNA-binding pocket, yet each of the variant proteins
displays some defects in at least one of the following phenotypes; camphor resistance,
regulation of the rpoS and rcsA, and ssDNA binding as measured by tryptophan
fluorescence (Table 2).
The two amino acid changes that affect the predicted DNA binding site of CspE
(Ec), K9E and K59E, both significantly decrease DNA binding but do not affect
dimerization. It has been shown that the dimerization of B. subtilis CspB protein occurs
through the backbone interactions at the amino terminus to the proteins (126). Amino
acid side chains do not appear to play a role in dimerization (126). Both binding-site
changes decrease gene regulation but only K9E completely abolishes the ability to confer
camphor resistance. K59E still confers some camphor resistance retaining the ability to
protect the chromosome from unfolding.
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Table 2. Summary of the phenotypes and biochemical properties of the CspE variants.

Phenotypes

Biochemical Properties

Gene Regulationb of:
Allele

Resistance to
Camphora

rcsA

rpoS

Tryptophan
Quenchingc

apparentd
KD

Dimer
Formation e

WT

1000 Fold

100%

100%

95%

28 nM

Y

K9E

0 Fold

33%

18%

18%

ND

Y

K59E

100 Fold

71%

80%

50%

271 nM

Y

I4E

0 Fold

56%

59%

75%

49 nM

Y

V29M

100 Fold

132%

32%

80%

44 nM

Y

A45P

0 Fold

61%

60%

65%

381 nM

Y

a

Resistance to camphor was measured by viable cell count in E. coli K12 cells (strain MC4100) containing
a 2 kb region of the E. coli chromosome cloned into pBR322 (pNT2). pNT2 is the original camphor
resistance conferring plasmid (Hu, et al. 1996). The mutations were constructed in vitro using site-directed
mutagenesis and all mutation-containing genes were sequenced. pNT2 containing wt cspE leads to 1000
fold more viable cells after camphor treatment than E. coli containing pBR322 ((D. Johnston, Ph.D.
Dissertation, Duquesne University 2007).
b

Gene regulations was measured using either an rcsA-lacZ fusion or an rpoS-lacZ fusion, pNT2 (wt cspE)
results in a 5-fold induction of the rcsA-lacZ as compared to pBR322 and a 7-fold induction of rpoS-lacZ.
In this table, these induction levels are set to 100% for wt cspE (D. Johnston, Ph.D. Dissertation, Duquesne
University 2007).
c

CspE contains a single tryptophan residue and it is surface exposed and in the predicted DNA binding
site. CspE binds to poly d(T) single stranded DNA and tryptophan fluorescence is quenched upon binding
(Johnston, et al. 2006). Percent quenching refers to the amount of fluorescence from the CspE protein in the
presence of DNA as compared to the absence of DNA.
d

Apparent KDs were determined using curve-fitting to titration curves as described (D. Johnston, Ph.D.
Dissertation, Duquesne University 2007, Johnston, et al 2006)
e

Dimerization was determined using both chemical crosslinking and FPLC as described (D. Johnston,
Ph.D. Dissertation, Duquesne University 2007).
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The three amino acid changes that are external to the DNA binding site (I4E,
V29M, A45P) do not exhibit any discernible patterns. They all dimerize and bind to DNA
with fluorescence quenching levels between 65-80% of wild type levels when tested.
Two variants (I4E and A45P) have decreases in expression on both genes tested and
confer no camphor resistance. The other change, V29M, shows an increase in regulation
on one gene and a decrease on the other, and exhibits a significant level of camphor
resistance. Based on the assays the lab has used to date (N. Trun, pers. communic.), the
mutants and resulting altered proteins have given limited information about the structure
and function relationship of CspE (Ec).

Stability of the Csps
CspB from B. subtilis has been shown to be resistant to degradation by trypsin in
vitro when it is bound to DNA (129). In E. coli, the CspE and -D proteins are stabilized
in vivo in cells missing the Lon protease. In these cells, the Csp proteins were
overexpressed from a plasmid residing in a strain deleted for the lon gene (118). Thus, I
investigated the role of protein stability for CspE (Ec) in the absence or presence of
single-stranded DNA, for CspE (Ec). The CspE (Ec) variants with amino acid changes
were also studied to determine if protein stability was altered. I originally tried to use
purified Lon protease for these studies but purifying optimally active Lon protease
proved not feasible. Instead, I chose to study CspE stability using trypsin, similar to the
B. subtilis studies (129).
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Wild type CspE
The enzyme trypsin cleaves peptide bonds on the C-terminal side of arginine and
lysine residues (155). The amino acid sequence of CspE (Ec) was analyzed for trypsin
digestion sites (Figure 16). This analysis shows that CspE (Ec) has a total of eight trypsin
cleavage sites, and four of these sites are located in the predicted DNA binding site of
CspE (Ec) (Figure 16).

Figure 16: The trypsin digestion analysis of the CspE (Ec) amino acid sequence. The amino
acid sequence of CspE (Ec) contains a total of eight trypsin digestion sites. The first four of these
digestion sites are located in the ssDNA-binding site of the protein in position 3, 5, 9 and 15. This
image is a screen shot of the results from ExPASy.com (156)

Trypsin digestion of CspE (Ec) indicated that CspE is rapidly degraded, with no
protein visible on a gel after 15 minutes of incubation at 37°C resulting in a half-life of ~
4 minutes (Figure 17). When CspE is incubated with an oligonucleotide containing 15
thymidine residues (poly (dT)15) ( preferred ligand of CspE), followed by treatment with
trypsin, CspE is still present after 60 minutes (Figure 17). The presence of poly (dT)15
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increases the half-life of CspE, with >90 percent of the protein remaining after 60
minutes (Figure 18).
To examine the structure of wild type CspE (Ec), CD spectroscopy was carried
out. Structural analysis of CspE (Ec) in the absence of DNA displays the normal signal
for the predicted beta barrel structure of an OB fold protein (Figure 19). This can be seen
by comparing the data in Figure 19 with the CD spectroscopy data for CspB (Bs) shown
in Figure 7.
Next, I investigated the effects of 6 variants in wild type CspE (Ec). The variant
proteins I4E, K9E, V29M, A45P, K59E and K59R were purified by passing cell lysate of
induced cells through a series of anion, cation, hydrophobic, and sizing columns (92).
These variants were analyzed for protease sensitivity and structural differences via CD
spectroscopy.

CspE /Trypsin

7 Kd

CspE/T15/
Trypsin
CspE

m 0 4 15 30 60

K 0 4 15 30 60

Figure 17: Gel electrophoresis of 40 μM CspE incubated with 3 μM trypsin, 3 μM trypsin +
40 μM of poly (dT)15 at 37°C. Ten microliter aliquots were removed at 0, 4, 15, 30, and 60
minutes for each condition. K is a control containing protein and buffer alone. Each time point
was analyzed using Quantity 1.0 for densitometry.
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CspE Degradation
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Figure 18: CspE degradation in the presence or absence of ssDNA. This graph shows the
percent remaining of 40 μM CspE incubated alone (red), with 3 µM trypsin (blue), or with 3 µM
trypsin + 40 µM of ssDNA poly (dT)15 (green). Aliquots were removed at 0, 4, 15, 30, and 60
minutes for each condition. The gel bands were analyzed using Quantity 1.0 for densitometry.
The data represents the average of the 3 experiments +/-S.E.

CspE
5
[Θ]MRW(103 deg cm2 decmol-1)

4
3
2
1
0
-1

199

209

219

229

239

-2
-3
-4
-5

Wavelength (nm)

Figure 19: The CD spectroscopy profile of wild type CspE (Ec). This spectrum displays the
-barrel signature signal seen in the three Csp homologues of B. subtilis.
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Analysis of The K9E Variant
The lysine located at position 9 of the amino acid sequence is predicted to play a
role in DNA binding by CspE. In vivo phenotypic analysis indicates that cells containing
the variant protein CspE (K9E) have significant defects in all phenotypes (Table 2).
Strains containing the K9E mutation are sensitive to camphor and have significant
decreases in expression of both rcsA and rpoS. The variant protein has only 18%
tryptophan quenching upon interaction with ssDNA. Degradation kinetics of CspE (K9E)
shows that the protein is very rapidly degraded by trypsin at 37°C, even if ssDNA is
present. This variant appears to be unstable with no detectable protein present even
without the presence of trypsin (Figure 20). Purified CspE (K9E) binds to ssDNA
significantly less than any of the other variant proteins tested and wild type CspE (Ec)
(Table 2 and Figure 20). The structural analysis via CD spectroscopy analysis of CspE
(K9E) shows that this variant, in the absence of DNA, exists as random coil (Figure 21).

Analysis of The K59E Variant
Strains containing the mutation expressing CspE (K59E) are still resistant to
camphor (although there is 10-fold less resistance than WT strains) and show gene
regulation of rcsA and rpoS at levels ~ 70-80% of WT. Tryptophan quenching analysis
using pure protein shows a 50% decrease in the quenching of the surface exposed
tryptophan in CspE (K59E) in the presence of ssDNA (Table 2). The KD is 10-fold more
than WT CspE. It forms dimers in solution and is stable in vitro (Table 2). The variant
K59E is more resistant to degradation by
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Figure 20: The degradation kinetics of the variant K9E. The half-life of K9E is 2 minutes for
three protein incubated alone (red) with 3 µM trypsin (blue) and 3 µM trypsin + 40 µM of ssDNA
with poly (dT)15 (green). The trypsin digestion shows that K9E is more unstable than wild type
CspE. Data shown represents experiments conducted in triplicate +/- S.E.
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Figure 21: The CD spectroscopy profile of the variant K9E. The CD signal for the variant
K9E (blue) indicates that this variant does exist in a random coil state not the typical beta barrel
structure as seen with the same analysis as WT CspE (red) (Figure 19). The CD signal for CspE
(Ec) (red) is compressed to fit the entire CD signal for the variant K9E (blue).
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trypsin in the absence of ssDNA than wild type CspE (Figure 22). At 15 minutes, there is
no WT CspE remaining when it is incubated with trypsin, while at 60 minutes, there is
approximately 50% of the K59E remaining when it is incubated with trypsin.

K59E Degradation Assay
120

Percent Remaining

100
80
K59E

60

K59E/Trypsin

40

K59E/T15/Trypsin

20
0
K

0

4

15

30

60

Time in Mins

Figure 22: The degradation kinetics of the variant K59E. The half-life of K59E is similar for
the protein alone (red) and when incubated with ssDNA and trypsin (green). The graph shows
that K59E is more resistant to degradation that wild type CspE. Data shown represents
experiments conducted in triplicate +/- S.E.

Sequence analysis shows that the K59E mutation is located in the predicted
binding sites (Figure 11). The CD spectroscopy analysis of this variant protein in the
absence of ssDNA indicates that the structure does not form the typical beta barrel as the
wild type protein (Figure 23). Instead the variant displays a CD signal similar to an alpha
helix.
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Figure 23: The CD spectroscopy profile of the variant K59E. The signal for the variant K59E
(blue) indicates that this variants does not exist the typical beta barrel structure as seen with the
same analysis as WT CspE (red).

Analysis of The I4E Variant
Strains containing I4E are sensitive to camphor and have about 60% of the gene
regulation levels of WT for both rcsA and rpoS (Table 1). I4E binds to DNA similar to
the wild type protein with 75% quenching of the tryptophan and a KD that is increased 2
fold as compared to WT CspE. It forms dimers in solution. The protein is stable in
solution, much like wild type CspE. A difference from wild type can be seen in the
degradation assays (Figure 24). Trypsin digestion of I4E in the presence of poly (dT)15
shows that I4E binds ssDNA similar to wild type and is protected from trypsin. However,
when digested with trypsin in the absence of DNA, the variant is degraded faster than
wild type CspE. This increase in degradation is the only defect in I4E found to date.
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Sequence analysis shows that I4E is not located in one of the predicted binding
sites (Figure 11). A structural analysis of I4E was conducted via CD Spectroscopy. The
analysis indicated that I4E has an alternate structure compared to that of wild type CspE
(compare Figures 19 and 25). I4E has partially unfolded from the normal beta barrel
-sheet (Figures 19 and 25).
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Figure 24: The degradation kinetics of the variant I4E. This graph shows the percent
remaining of 40 μM protein incubated alone (red), with 3 μM trypsin (blue) or with 3 μM trypsin
and 40 μM of ssDNA with poly (dT)15 (red).
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Figure 25: The CD Spectrum of the variant I4E. The spectrum of the variant I4E (blue)
indicates that is has partially unfolded from the normal beta barrel structure to that of a -sheet.
The CD spectrum of CspE (Ec) (red) is shown for comparison.

Analysis of The V29M Variant
Cells containing the V29M mutation in cspE are still camphor resistant (10-fold
less resistant than WT strains) (Table 1). Gene regulation is drastically altered, depending
upon which reporter gene is examined. V29M binds ssDNA only 15% less than wild type
CspE and forms dimers in solution (Table 1). Trypsin digestion of CspE (V29M) results
in hyper degradation in the absence of ssDNA when compared to wild type (Figure 26).
This variant is also sensitive to degradation in the presence of poly (dT)15, resulting in
approximately 40% less protein at the 60 minute time point versus the wild type protein
which remains at 90% at the same time point (Figure 26).
Sequence analysis of the variant V29M shows that this amino acid change is
located outside of the predicted binding site (Figure 11). Structural analysis via CD
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spectroscopy indicates that this variant has partially unfolded from the normal beta barrel
-sheet (Figure 27).

Figure 26: Degradation kinetics of the variant V29M. The CspE variant V29M is only
partially protected from protease degradation by the presence of ssDNA (green). The protein is
stable for more than 60 minutes at 37°C in buffer alone (red). In the presence of trypsin and
absence of ssDNA the variants V29M has a half-life of ~2 minutes (blue) compared to wild type
which is ~4 minutes (Figure 18). Data shown represents experiments conducted in triplicate +/S.E.
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Figure 27: The CD Spectrum of the variant V29M. The spectrum of the variant I4E (blue)
indicates that is has partially unfolded from the normal beta barrel structure to that of a -sheet.
The CD spectrum of CspE (Ec) (red) is shown for comparison.

Analysis of The A45P Variant
Strains containing the A45P mutation in cspE are sensitive to camphor yet still
exhibit approximately 60% of the gene regulation of both rcsA and rpoS, when compared
to WT strains. CspE (A45P) binds ssDNA significantly worse than wild type, exhibiting
65% quenching of the tryptophan and a KD that is 10 greater than WT CspE (Table 1). It
forms dimers in solution and the protein is stable. Trypsin digestion of A45P displays
hyper-degradation (Figure 28). In the presence of ssDNA, this variant is degraded faster
than any of the others, resulting in a (t1/2) of ~15 minutes. The variant protein without
trypsin present is stable up to 60 minutes at 37º C (Figure 15).
Sequence analysis shows that A45P amino acid change is located outside of the
predicted binding site (Figure 11). Structural analysis of the variant protein A45 via CD
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spectroscopy indicates that this variant is denatured from its native OB-fold conformation
(Figure 29).
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Figure 28: The variant A45P degradation kinetics. The CspE variant A45P is only partially
protected from protease degradation by the presence of ssDNA. The protein is stable for more
than 60 minutes at 37 °C in buffer alone (red). In the presence of trypsin, the variant A45P has a
half-life of ~2 minutes, compared to wild type which is ~4 minutes (Figure 19). The half-life of
A45P in the presence of ssDNA is ~ 15 minutes (green), compared to wild type CspE which is
60+ minutes. Data shown represents experiments conducted in triplicate +/- S.E.
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Figure 29: The CD spectrum of the variant A45P. The spectrum of this variant indicates that
the variant protein A45P results in a denatured protein (blue). The CD spectrum of CspE (Ec)
(red) is shown for comparison.
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Analysis of The K59R Variant
In Figures 11 and 14, it can be seen that the Csp proteins fall into two classes
when residue 59 is considered. Csp A, B, C, D, E and I contain a lysine residue at this
position. Csp-G, -H, -I and CspB from B. subtilis contain an arginine at this
position. Given that this residue is strongly implicated in DNA binding, I wanted to
determine what effect making the K59R mutation has on the function of CspE. The
mutation changing the amino acid at position 59 from a lysine to an arginine was
introduced using the Quick Change system from Invitrogen.
The mutated gene was sequenced to confirm that only the expected change was
present. After overexpression and purification, tryptophan quenching of CspE (K59R) by
ssDNA much is 50% lower than wild type CspE (Ec). Degradation kinetics of this variant
protein show that it is well protected from degradation in the presence of ssDNA with a
half-life of over 60 minutes (Figure 30), comparable to wild type CspE (Ec). The protein
alone however is more resistant to trypsin degradation when ssDNA is removed, with a
half-life of ~25 minutes (Figure 30). In the presence of trypsin, wild type CspE (Ec) has
a half-life of only 4 minutes when ssDNA is present. This variant is results in a 50%
reduction in tryptophan fluorescence quenching compared to wild type CspE (Ec) (Figure
31).
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Figure 30: The degradation kinetics of the variant K59R. This graph shows the percent
remaining of 40 μM protein incubated alone (red), with 3 μM trypsin (blue) or with 3 μM trypsin
and 40 μM of ssDNA with poly (dT)15 (green). Data shown represents a minimum of 3
experiments +/- S.E.
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Figure 31: The ssDNA quenching of tryptophan fluorescence in wild type CspE (Ec) and its
variants. Each of the proteins has a single surface exposed tryptophan whose fluorescence is
quenched by the binding of ssDNA. The graph shows the percentage of tryptophan fluorescence
for each of the proteins. Data shown represents a minimum of 3 experiments +/- S.E.
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Summary of the CspE Variant Characteristics
The phenotypes of cells containing mutations in cspE and the biochemical
properties of the resulting protein variants are summarized in Table 2. These data indicate
that protein stability plays an important role in the function of CspE. Each mutant will be
discussed in the context of stability and phenotypes in the Discussion.

Molecular Screening and Docking
Using the computational model of CspE (Ec) (Figure 32) with a calculated RMSD
of 1.01 Å, two database subsets containing a total of 3,025,534 individual molecules
(Table 3) were downloaded from the free online ZINC database (157). The databases
were screened for lead compounds that could inhibit the ssDNA binding function of
CspE (Ec). The structural features of the DNA molecule that binds to CspB (Bs) were
used as the template for ligand selection (Figures 32 and 33). This method allowed us to
find molecules in the databases that are similar in structure to that of the ssDNA ligand
resulting in a highly selective screening.
The first subset of molecules from the online ZINC database lead-like group
contained a library of commercially available compounds. Each subset was filtered to
remove solvent molecules from the files and partial charges were added to optimize their
electrostatic potential. A conformational search of a 25,764 molecules within the first
database resulted in a total of 1.8 million possible molecular conformations (Table 3).
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Figure 32: The superimposed structures of the experimentally determined structure of
CspB (Bs) (yellow ribbon) crystalized with its ssDNA ligand (black ball and stick) and the
CspE (Ec) homology model (green ribbon). The RMSD of the two structures is 1.01 Å. This
comparison was used to predict the ssDNA-binding site in CspE. The figure was generated using
MOE version 2011.1.
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Figure 33: The 3D ligand/protein interaction analysis of the CspB (Bs). The five structural
features of the DNA (yellow stick figure) chosen are shown in neon green, orange, purple and
blue spheres. See text for details. This figure was generated using MOE version 2011.1.

Table 3. Database statistics
Subset

Number
Of
Molecules

Number
Of
Conformations

Time To
Run
Each Subset

Number Of
Hits

Top Hit

0.0

25,746

1,623,776

3 months

16

ZINC
13065016

0.0-0.5

1,064,044

2,220,913

1.5 months

370

ZINC
31346808
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All databases were filtered for violators of Lipinski’s rule of five (158). This
process excludes any molecules from the database that fails to meet at least three of the
following criteria:
1) The molecule must not contain more than five hydrogen bond donors.
2) The molecular weight of the molecule must be less than 500 Daltons.
3) The Log P, which is a measure of the compounds lipophilicity, must be less than five.
This increases the molecules chances to pass through the membrane.
4) The molecule must have fewer than ten hydrogen bond acceptors.
The databases were filtered for toxic compounds. The toxic properties are often
related to chemical structure, more specifically, to particular substructures, that are
generally identified as toxicophores (159). This process excludes molecules in the
database that contain any of the known toxicophores.
Each molecule in the filtered database was docked to the computationally
determined binding site of CspE (Ec) using 5 features (1 hydrophobic ring, 1 hydrogen
bond donor and 3 hydrogen bond acceptors) of the DNA ligand for screening (Figure 33).
The molecules were then docked to the chosen binding site of the protein and this
resulted in a total of three compounds that could potentially bind to the selected CspE
(Ec) binding site.
The first molecule tested in this screen was labeled ADS-1 (Antimicrobial Drug
Screen #1) (Figure 34). The lack of solubility in water of this compound in water required
the search for a suitable solvent that would not affect the structure of the protein. The CD
spectrum of wild type CspE (Ec) protein was analyzed in 10 % DMSO and 10% 2propanol (Figure 35). The DMSO proved to alter protein structure, however 2-propanol
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did not result in any significant changes in the structure of CspE (Ec) (Figure 35). 2propanol was used to solubilize ADS-1 and will be used for other compounds not soluble
in phosphate buffer alone.
The compound ADS-1, interfered with ssDNA binding to wild type CspE (Ec) in
the trypsin degradation assay. In the presence of ADS-1 and poly (dT)15, CspE is more
susceptible to degradation by trypsin than CspE plus poly (dT)15 alone (Figure 36).
ADS-1 leads to ~ 30% decrease in CspE fluorescence after 60 minutes. In these assays,
twice as much CspE (40 mM) was present as ADS-1 (20 mM) and poly (dT)15 (20 mM).
ADS-1 was analyzed for its ability to inhibit bacterial growth on minimal agar. As
a first step, a disk diffusion assay was used (Figure 37). A lawn of bacterial cells was
plated in top agar on agar plates. Small sterile filter paper disks (~5mm) were applied to
quadrants of the agar plate and 10 μl of 200, 100 and 50 mM concentrations of the
compound and buffer alone were spotted on each disk. Zones of inhibition around each
disk were measured after 16 hours of growth at 37C. ADS-1 produced no zones of
bacterial growth inhibition on LB rich medium, M63 minimal medium with 0.2%
glucose, and M63 minimal medium with 0.2% glycerol at 37C (Figure 37).
The second subset of compounds to be analyzed was prepared the same as
previously described, with one exception. For our second screen and docking simulation,
the target sites were selected based on the mapped poly (dT)7 interactions with CspB
(Bs), as found in the co-crystal (125).
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Figure 34: The structure of the first virtual screen candidate molecule, ADS-1. The structure
of the lead compound ADS-1 contains hydrophobic ring structures similar to that of the ssDNA
ligand that binds to both CspE (Ec) and CspB (Bs). This figure was generated using MOE version
2011.1.
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Figure 35: The CD spectroscopy analysis of CspE (Ec) in various solvents. The graph shows
CspE in phosphate buffer alone (blue), phosphate buffer with 10%DMSO (red), and phosphate
buffer with 10% 2-propanol (green).
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Figure 36. The effects of ADS-1 on protection of wild type CspE (Ec) by poly (dT)15 ssDNA.
ADS, 3 μM trypsin and 40 μM of poly (dT)15 DNA
(red), 3 μM trypsin (blue). Ten microliter aliquots were removed at 0, 4, 15, 30, and 60 minutes
for each condition and electrophoresed on SDS PAGE gels. Gel bands was analyzed using
Quantity 1.0 for densitometric analysis. Assays were repeated a minimum of 3 times and the S.E.
was calculated.
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Figure 37: The disk diffusion assay of ADS-1. Concentrations of (1) 25, (2) 50, (3) 100 mM of
ADS-1 showed no inhibitory effects on E. coli K12 MG1655 (wild type strain). The solvent 10%
propanol (4) was used as a control. Experiments were replicated a minimum of 3 times.
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The co-crystal poly (dT)7-CspB (Bs) was superimposed with the computational
model of CspE (Ec) and used to model and predict ssDNA interactions with CspE (Ec)
(Figure 38). Amino acid residues that were shown to directly interact with the ssDNA
ligand were chosen as the docking site. The residues selected were K9, F19, and F30 in
the CspE (Ec) sequence (Figure 38). These residues show an identical alignment with the
residues, K7, F17 and F28 in CspB (Bs) and play a role in ssDNA binding (Figure 11).
The screening and docking simulation produced the compound ADS-2 (Z193696940) as
the top hit out of 370 possible compounds that fit the pharmocophore query and bind to
the selected docking sites (Figure 39). The subset contained approximately 1.8 million
compounds, meaning that 0.02% of the molecules in this subset fit the selected
parameters.
The compound ADS-2 was examined for its ability to inhibit ssDNA binding by
CspE. When 200 μM ADS-2 was incubated with 40 μM CspE for 5 minutes, followed by
the addition of 40 μM poly (dT)15, the percent of CspE remaining dropped from 100% to
60% at 60 minutes (Figure 40). To determine if there are any order of addition effects on
the binding, CspE was incubated with poly (dT)15 for 5 minutes and then ADS-2 for 5
minutes followed by digestion with trypsin. The percent of CspE remaining dropped from
100% to 90% over 60 minutes. This suggests that ADS-2 does not efficiently dislodge
ssDNA from CspE but that it can bind to free CspE and prevent the ssDNA from binding
and protecting the protein from degradation by trypsin.
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Figure 38: The 2-D ligand interaction map. This interaction map is of the superimposed
structures of CspB crystal structure from Bacillus subtilis and the CspE homology model from E.
coli. K12 (Figure 28). CspE residues are labeled as A and CspB residues labeled as B. The poly
(dT)7 ssDNA ligand is shown as in black. Lysine B7 and A9 interact directly with the DNA
ligand. Disruption of this interaction may decrease binding function. This figure was generated
using MOE version 2011.1.
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Figure 39: The synthesis scheme and structure of ADS-2 (Z193696940). This synthesis
scheme was provided by Enamine, Inc.

ADS-2 was analyzed for its ability to inhibit bacterial growth on minimal M63
media with 0.2% glucose. As a first step, a disk diffusion assay (as described above) was
used (Figures 39 and 40). Zones of inhibition around each disk were measured after 16
hours of growth at 37 previously described. The disk diffusion assay shows that
concentrations of 50 mM or 100 mM of ADS-2 can inhibit growth of E. coli K12
MG1655 (wild type strain). ADS-2 was also tested on three mutant strains of E. coli
containing deletions of various csp genes (ΔE, ΔACE, and ΔDHAC). Mutant strains that
were missing CspE (Ec) displayed slightly larger zones of inhibition than MG1655 and
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ΔDHAC (Figure 41). Other bacterial species tested against the compound included
Serratia marcescens, Klebsiella pneumoniae, Staphylococcus aureus and Pseudomonas
aeruginosa. There were no inhibitory effects of ADS-2 on these bacteria.
The virtual screening and docking methods used resulted in over 300 molecules
with the potential to bind to CspE (Ec). This process involved building a computational
model, predicting and selecting the docking site of the CspE protein and using the
structural and chemical properties of the ssDNA ligand as a template for small molecule
screening of potential inhibitors (Figure 43). The first two compounds, ADS-1 and ADS2, both demonstrated the ability to disrupt ssDNA binding. However, only ADS-2
demonstrated the ability to inhibit cell growth of WT CspE and various Csp deletion
strains.
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Figure 40. The effects of ADS-2 on protection of wild type CspE (Ec) by poly (dT)15 ssDNA
μM trypsin, 20 μM
ADS, 3 μM trypsin and 40 μM of poly (dT)15 DNA
(red). Ten microliter aliquots were removed at 0, 4, 15, 30, and 60 minutes for each condition and
electrophoresed on SDS PAGE gels. Gel bands were analyzed using Quantity 1.0 for
densitometric analysis. Assays were repeated a minimum of 3 times and the S.E. was calculated.
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Figure 41: The disk diffusion assay for ADS-2. Tested concentrations of 50 mM and 100 mM
ADS-2 were analyzed for their inhibitory effects on WT E.coli and three csp deletion mutants A).
The photograph shows the diameters of the zones on inhibition B). The size of the zones of
inhibition were measured in mm. Concetrations of compound less than 50 mM had no inhibitory
effects. Results represent the average of three experiments +/- S.E.

80

Figure 42: The flowchart showing the strategy for searching for antimicrobial compounds
using the Csp proteins as a target.

81

DISCUSSION
The Csp Proteins in E. coli Can Be Grouped into Different Classes Based on Structure
and Surface Analysis
The Csp proteins are very prevalent in bacteria with 80% of sequenced bacterial
genomes containing either a functional or potential csp coding region. Most bacteria
contain more than one csp gene. The two most well studied bacteria with respect to csp
genes are B. subtilis and E. coli K12. B. subtilis contains three csp genes and E. coli K12
contains nine csp genes. The work presented here has accomplished two main goals:
First, I determined some of the structure-function relationships for CspE, the major Csp
protein expressed under slow growth conditions in E. coli K12. Second, I determined
that the nine E. coli K12 Csp proteins share enough functionality such that a single small
molecule has the potential to inhibit them.
Beginning with the primary amino acid sequence for the nine E. coli K12 Csp
proteins, alignments indicate that the Csp proteins share between 29% and 83% amino
acid identity along the length of the polypeptide chain. Molecular computational software
(MOE) was used to model each of the Csp proteins, using the published crystal structure
of CspB from B. subtilis as the reference structure. Alignment and superimposition of the
nine models generated with CspB (Bs) as the template, shows they are very similar as far
as backbone structure and electrostatic surfaces are concerned.
The first difference I noted is that CspF (Ec), CspG (Ec) and CspH (Ec) contain a
positive extension that is not present in the rest of the Csp proteins in E. coli K12 (Figure
15). This extension is produced by the presence of an arginine residue (at position 59
when using the sequence of CspE as the reference sequence) that is changed to a lysine in

82

the other five Csp (Ec) proteins. The arginine residue is present in CspB (Bs) and is one
that has been implicated in ssDNA interactions (127) (Figure 11). While the residues are
similar in chemical properties, there is a structural protrusion that is present with the
arginine that is not present with the lysine in that same location. The amino acid arginine
has a molar mass of 174.2 gm while lysine has a molar mass of 146.19 gm. This
difference in mass between the two could contribute to the structural difference seen
between those two amino acids. Structurally, I can classify the nine Csp proteins of E.
coli. K12 into 2 groups: 1) the closed fist conformations where the globular structure
resembles a closed fist (CspA, B, C, D E and I (Ec)) and 2) the hitchhiker conformation
where the structure resembles that of a closed fist with the thumb extended (CspF (Ec), G
(Ec) and H (Ec)) (Figure 14).
To determine if there are measurable differences between an arginine at position
59 and a lysine at position 59, I investigated the effect of replacing the lysine codon at
position 59 of cspE (Ec) with an arginine codon. Both arginine and lysine resulted in
similar protection of the corresponding purified protein from protease degradation in the
presence of ssDNA (Figure 30). Interestingly, arginine at position 59 of CspE displayed a
lower level of tryptophan quenching in the presence of ssDNA, yet it had a greater
resistance to trypsin digestion when no ssDNA was present. These data suggest that the
arginine at this position may increase stability of the protein making it more resistant to
protease degradation. Because CspE is rapidly degraded when not bound to ssDNA,
increasing the stability of the protein gives it more time to bind to its ligand and
effectively increases the concentration of protein.

83

A second difference I noted between the Csp proteins can be seen on the
hydrophobic surface map analysis (Figure 15). Hydrophilic residues are shown in pink,
neutral in white and lipophilic in green. I designated the receptor atoms to be taken into
account, and designated the distance or cutoff for which the map should be created
allowing me visualize the different surface maps (hydrophobic and electrostatic). The
lipophilic maps of the Csp proteins of E. coli K12 possess a hydrophobic patch present in
the DNA-binding pocket on 7 of the 9 models (Figure 15). Both CspF (Ec) and CspH
(Ec) are missing this hydrophobic patch (Figure 15). In cold shock-related proteins that
have been shown to bind ssDNA, this area contains six aromatic residues (Trp8, Phe15,
Phe17, Phe27, Phe30, and Phe38) that are involved in ssDNA binding (127, 160). While the
functions of CspF (Ec) and CspH (Ec) have yet to be elucidated, using the data from the
homology models, I would predict that these two proteins do not function in sequence
specific ssDNA binding or may not bind as well as the other Csp proteins that do contain
the hydrophobic patch.
I created surface maps for the electrostatic regions on each Csp, where a negative
charge is coded red, a neutral charge is coded white, and a positive charge is blue (Figure
14). These maps indicate that the surface charges are not concentrated in specific regions
or clusters. Rather, the charges are interspersed across the entire three-dimensional
surface of each protein. These maps give a reasonable explanation for why none of the
Csp proteins purified to date bind to either an anion or a cation resin during purification.
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The Comparison of CspB (Bs) & CspE (Ec) Biochemical and Structural Functions
As a first step to investigate the potential differences in Csp proteins predicted by
the modeling, I investigated some of the biochemical properties of CspE (Ec). I examined
the CD spectrum for purified CspE protein and compared it to the published CD spectrum
for CspB (Bs). The CD spectroscopy analysis shows that the CspB (Bs) and CspE (Ec)
proteins are similar in structure (Figures 7 and 19), indicating that CspE (Ec) is an OB
-barrel structure. These data coupled with the high degree of amino
acid sequence similarity demonstrates that the CspB (Bs) homologue makes an excellent
template for homology modeling of CspE (Ec).
I have investigated the degradation kinetics of CspE (Ec) in both the presence and
absence of ssDNA. Previous data from CspB (Bs) has indicated that CspB (Bs) is
protected from degradation when it is bound to DNA (129). Incubation of CspE with
trypsin shows a decrease in CspE levels with a half-life (t1/2) of ~ 4 min and CspE is
protected from trypsin digestion when ssDNA is present (Figure 18). It has been recently
reported in the literature that CspD (Ec), is a target of Lon degradation (94) and previous
studies in our lab show that the accumulation of CspE (Ec), is only detectable in Δlon
cells when analyzing whole cell extract via SDS-page (118). Due to the high sequence
identity among the Csps, I investigated the degradation kinetics of CspE (Ec) with Lon
protease and found that CspE (Ec) is indeed degraded by partially purified Lon protease
(data not shown). I was not able to routinely purify active Lon and, thus, chose to
examine CspE degradation using trypsin, as has been published for CspB (Bs) (129).
If in vitro proteolysis mimics in vivo conditions, the DNA binding function of
CspE may be required for its stability in the cell. Degradation of Csp molecules that are
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not bound to ssDNA could provide a means by which the concentrations of Csps in the
cell are regulated. Thus, small molecule inhibitors of CspE (Ec) ssDNA binding should
render the protein and its homologues more susceptible to degradation. I used this
information to establish a means to screen for inhibitors of ssDNA-binding of CspE (Ec)
(Figure 41).
Csp Variant Analysis
Variants of cspE (Ec) were created both through targeting specific amino acids for
site-directed mutagenesis and through random mutagenesis (C. Hall, O. Sand and N.
Trun, unpublished results). I purified the CspE (Ec) variant proteins I4E, V29M, A45P,
K59E, and K9E from cells containing the respective T7 inducible clones using column
chromatography (anion, cation, hydrophobic, and sizing columns). The proteins were
assayed for DNA binding using the tryptophan quenching assay and poly (dT)15, and
stability using acrylamide gel electrophoresis (my work). Dimerization using FPLC and
crosslinking studies were previously carried out (Table 2 and D. Johnston, pers.
communic.). In vivo, cells carrying the variant cspE genes were assayed for regulation of
rcsA and rpoS, using either an rcsA-lacZ fusion or an rpoS-lacZ fusion (Table 2). Their
ability to condense DNA was monitored using a camphor resistance assay (Table 2). To
complete the analyses of the Csps, protease sensitivity in the presence and absence of
ssDNA was examined and structural analysis of wild type CspE (Ec) and the variants was
performed using circular dichroism spectroscopy.
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Variant CspE (I4E)
The phenotypic assays indicate that, in vivo, I4E is defective in regulatory
expression of both rcsA and rpoS and defective in protecting the chromosome from
decondensation (camphor sensitive) (Table 2). The variant I4E and wild type have similar
binding affinities for ssDNA and are equally protected from protease degradation by the
presence of the ssDNA (Table 2). CD spectroscopy analysis shows that this mutant has
lost its native structure and it is degraded faster than wild type in the absence of of bound
ssDNA. This suggests that a loss in native structure results in hyper-degradation and
decreased ability to regulate genes and protect the chromosome.
If the major defect in I4E is hyper-degradation of the protein when not bound to
DNA, then the amount of I4E in the cells should be lower than the amount of wild type
protein. Given that all three in vivo phenotypes are defective, the amount of I4E is not
sufficient to result in wild type phenotypes. I4E indicates that the levels of CspE in the
cell are critical. These data also suggest that the cell does not respond to decreased levels
of CspE by synthesizing more of it to compensate.

Variant CspE (V29M)
V29M confers camphor resistance on the cells. Gene regulation studies indicate a
complex picture, with one gene showing a decrease in expression and the other an
increase in expression (Table 2). The V29M protein is degraded faster than wild type
CspE (Ec) in the absence of ssDNA and does display some loss of protection from
ssDNA in the degradation assay yet still has a half-life of greater than 60 minutes (Figure
22). The protein alone is stable at 37°C.
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The structural analysis of V29M via CD spectroscopy indicates that this protein is
-sheet secondary structure (Figure 23). This change in
structure has a direct affect on its degradation kinetics resulting in hyper-degradation
(Figure 22). Collectively these data do not support targeting valine 29 of the polypeptide
chain for small molecule inhibition of the Csps because some phenotypes are defective
and others are exaggerated.

Variant CspE (A45P)
The variant A45P shows a decrease in the regulation of both gene fusions, binds
ssDNA slightly less than wild type and is also camphor sensitive (Table 2). The variant
A45P has a general defect that affects how the protein behaves in all of the assays tested.
The variant protein A45P is degraded rapidly in the absence of ssDNA and the
presence of ssDNA provides very little protection resulting in a half-life of ~15 minutes.
Wild type CspE (Ec) is fully protected up to 60 minutes when ssDNA is present. The
protein alone is stable at 37°C. Collectively these data suggests targeting Alanine 45 of
the polypeptide chain for small molecule inhibition of the Csps may increase protein
degradation of wild type CspE (Ec).

Variants CspE (K59E and K59R)
K59E exhibits an intermediate level of camphor resistant and has decreased
expression of both genes tested (Table 2). The degradation kinetics of K59E show that a
change in Lysine 59 in the amino acid chain of CspE (Ec) results in less protection from
ssDNA yet the variant displays an increased resistance trypsin digestion (Figure 22). The
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variant K59E is slightly less stable alone and the addition of ssDNA does not
significantly change the degradation kinetics in the presence of trypsin (Figure 22). The
increase in stability could compensate for the decreased binding of the protein, giving
intermediate phenotypes for camphor resistance and gene regulation.
CD Spectroscopy data shows that this variant protein adopts an alternate structure
(Figure 23). Alternative conformations of native proteins can change structure and block
or reduce access to sequences for degradation. In this case the signal for degradation by
trypsin (C terminal side of arginine and lysine) may not be easily accessible to the
protease trypsin. The change in native structure may account for the reduced sensitivity to
trypsin degradation and some loss of ssDNA-binding ability (Figure 22). Collectively
these data do not support the targeting of Lysine 59 in the CspE (Ec) polypeptide chain
for small molecule inhibition of the Csps.
Sequence analysis of the nine Csp amino acid sequences reveals that lysine 59 of
CspE is conserved only among 6 of the proteins (CspA, -B, -C, -D, -E & -I (Ec)) (Figure
11). In contrast, the proteins CspB (Bs) and CspF, -H and –G (Ec) have a similar yet nonconserved arginine present at the same position (Figure 11).
I investigated the effect of replacing the lysine in position 59 of CspE (Ec) with
an arginine and found that change to result in similar protection from degradation in the
presence of ssDNA (Figure 30). Interestingly, this variant displays a lower level of
tryptophan quenching yet has a greater resistance to trypsin digestion when no ssDNA is
present. These data suggest that the arginine at this position may increase stability of the
protein making it more resistant to protease degradation.
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Variant CspE (K9E)
The K9E variant displays a significant loss in its ability to regulate genes, confer
resistant to camphor and bind ssDNA (Table 2). Structural analysis via CD spectroscopy
shows that the purified protein of this variant exists as a random coil (Figure 29). This
structural change not only results in loss of DNA binding but also results in the shortest
trypsin digestion half-life among wild type and the variant proteins (Figure 28). This
variant is not stable alone and the addition of trypsin and ssDNA does not affect its
stability (Figure 29). I expected this variant to be stable without trypsin present however
no detectable protein levels are present in any of the conditions (Figure 29). SDS page
analysis of purified protein shows no other detectable proteins besides the variant
however the instability of this variant may be due to protease contamination. No other
variant displayed this level of instability when incubated alone.
Alignment of the Csps shows that lysine 9 is the only residue that is conserved in
all nine Csps in E. coli and CspB (Bs) (Figure 11). This highly conserved lysine residue is
critical for normal function, structure and stability of CspE (Ec). Collectively this data
supports targeting Lysine 9 of the CspE (Ec) polypeptide chain for small molecule
inhibition of the Csps.
Alignment and superimposition of the nine models generated with CspB (Bs) as
the template, shows highly conserved regions including a lysine residue that is present in
all ten sequences (Figures 11 and 43). Using the modeling data, I predicted that the
variants K59E and K9E would reduce the DNA binding properties of the protein.
Likewise, I also predicted that mutations outside of the binding site (I4E, V29M and
A45P) would result in no major loss of the DNA binding function. Each one of these
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amino acid substitutions resulted in loss of CspE (EC) native structure (Figures 19, 21,
23, 25, 27 and 29). The DNA binding characteristics of the CspE (Ec) proteins with
single amino acids changes suggests that the CspE (Ec) model has functional validity.

Docking Simulation Using Lysine 9 and 59 as Targets
Using the homology model of CspE (Ec) and the data from the variant proteins, I
narrowed my choices down to 2 target sites for small molecule docking simulations. The
first choice was lysine 59 in the CspE (Ec) amino acid chain. This residue was chosen
because MOE computationally calculated this residue as interacting with the ssDNA, and
it aligns with one of the residues identified in ssDNA binding of CspB (Bs) (Figure 11).
The variant data for K59E showed that a substitution in this position affects a number of
the phenotypes seen in wild type CspE (Ec) including DNA protection and the secondary
structure of the protein (Table 2) (Figures 26 and 27).
Docking simulation using Lysine 59 as the docking target indeified ADS-1 as the
first potential inhibitor. Furthermore, this compound showed some interference with
ssDNA binding by wild type CspE (Ec). However, the disk diffusion assay showed no
inhibitory effects on bacterial cell growth. The compound is not soluble in water, making
it less attractive as a potential lead compound.
My final docking simulation was carried out using lysine 9 in the CspE (Ec)
amino acid chain as a target. This target was selected because it is highly conserved and
collectively the data shows that it is critical for the normal function, structure and
stability of CspE (Ec). Computational analysis indicated that lysine 9 is one of the
residues predicted by MOE to interact directly with the ssDNA ligand.
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Docking simulations using lysine 9 indentified ADS-2 as the lead candidate. This
molecule interfered with ssDNA binding and produced modest zones of inhibition in the
disk diffusion assays on minimal media in the presence of glucose (Figure 41). Since this
residue is highly conserved in all nine of the Csps in E. coli and there was also inhibition
in various Csp deletion strains. This compound may bind to all of the nine Csp proteins
(Figure 41).
Investigation of protein function requires understanding the polypeptide structure
and ligand interactions. The structure is ultimately determined by the protein’s primary
sequence. The use of homology modeling allows the accurate structural prediction of a
set of proteins that do not have solved experimental configurations. Modeling of the Csp
(Ec) proteins has given me testable predictions for each Csp protein. In the case of CspE
(Ec), my predictions of the binding site compositions were validated by the CD
spectroscopy and degradation kinetics of variant proteins.
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FUTURE DIRECTIONS
One of the Challenges of Drug Discovery
The process of drug discovery through molecular modeling and virtual screening
presents a number of challenges besides producing an accurate model and target site
selection. I have found that a major difficulty centers on the consistent synthesis of a
small molecule. The small molecule libraries that were used in this project contain
structural information uploaded by the company that synthesized them.
In one case, the compound ADS-2 was synthesized by Enamine, Inc. (Ukraine).
After initial testing DNA binding interference and inhibition of growth by the disk
diffusion assay I required more compound for further studies. Enamine, Inc. no longer
had a stock supply and synthesized a new lot of the compound using the synthesis
scheme in Figure 39. The company reported that a different chemist synthesized the
second lot of ADS-2 and the process took 10 weeks. Visual inspection of the compound I
received did not appear to be the same as my original drug candidate ADS-2. It was a
non-clumping white powder and the original compound was clumped and yellow.
The newly synthesized compound was not soluble in 2-propanol. This compound
produced a white cloudy solution when resuspended. In comparison original ADS-2 was
soluble in 2-propanol and the solution was a light red. Initial testing of the new lot of
ADS-2 produced no inhibitory affects on the growth of E. coli MG1655. The company
has yet to reproduce a compound that behaves the same as the original compound, both in
vivo and in vitro.
The success of this project relies the ability of the company to consistently
produce the molecule being tested. The alternative is to collaborate with a local chemist
to synthesize ADS-2 using the synthesis scheme we obtained from Enamine, Inc.
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Future Studies
Future candidates for small molecule inhibition of the E. coli by targeting Csps
will need to perform comparable to ADS-2 in both the binding and disk assays. If they
prove to inhibit ssDNA-binding and bacterial growth the compounds will need to be
evaluated further to confirm binding to the protein versus the ssDNA, as well as
examining the killing effects on mammalian cell cultures. Ideally, the candidate
molecules will need to have no adverse affects on mammalian cell culture and tolerance
levels of the compound in a murine model should be examined. I have not been able to
obtain these results for the current lot of ADS-2 because I had only a small amount (0.09
grams) of the compound remaining.
Experimental data collected using these assays should produce a candidate
molecule that successfully inhibits ssDNA binding, inhibits bacterial growth, does not
inhibit mammalian cell proliferation and proves non-toxic in a murine model. The
candidate molecule ADS-2 initially performed well in the first two of these assays.
Unfortunately studies could not continue until more of the compound I originally tested
can be produced. However, now that I have established a computational model, protocol
for the computational screening, as well as in vivo and in vitro experiments a new
candidate can be screened.
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